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Principal Investigator’s Statement: 
 
This protocol contains information that is confidential and proprietary to Celator 
Pharmaceuticals, the Sponsor.  This information is provided to me for the purpose of 
conducting a clinical trial for the Sponsor.  The contents of this protocol may be disclosed 
to study personnel under my supervision who need to know the contents for this purpose, 
as well as my Institutional Review Board(s) or Ethics Committee(s), subject to the 
following condition: the contents of this protocol may not be used in any other clinical 
trial and may not be disclosed to any other person or entity without the prior written 
permission of the Sponsor.  The foregoing shall not apply to disclosure required by 
governmental regulations or laws; however, I will give prompt notice to the Sponsor of 
any such disclosure. 
 
Any supplemental information that may be added to this document is also confidential 
and proprietary to the Sponsor and must be kept in confidence in the same manner as the 
contents of this protocol. 
 
I further agree to conduct the clinical trial referred to above in accordance with all 
applicable government regulations, Good Clinical Practice, the Sponsor’s guidelines and 
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PHASE III, MULTICENTER, RANDOMIZED, TRIAL OF CPX-351 
(CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND 




Celator Pharmaceuticals, Inc. 
Objectives: 
Primary 
• To confirm the efficacy of CPX-351 compared to “7+3” as first line therapy in elderly patients 
(60-75 years) with high risk (secondary) AML. The primary efficacy endpoint will be overall 
survival. 
• To confirm the safety of CPX-351 
Secondary 
• To confirm the improvement in achievement of morphologic leukemia free state1 
•  To confirm post-induction response (CR+CRi) rate (morphologic, cytogenetic and molecular 
response), remission duration (relapse-free survival), event-free survival and overall best post-
treatment response (CR+CRi) rate 
• To confirm the safety and practicality of CPX-351 as consolidation therapy 
• To assess serum copper elevations  
• To assess the population pharmacokinetics of CPX-351 in patients 
• To assess and compare pharmacoeconomic differences between the treatment arms 
 
Study Design: 
This study is an open-label, parallel arm, randomized study where newly diagnosed AML including t-
AML, AML in patients with a history of MDS or CMMoL, and de novo AML in patients with specific 
adverse karyotypic changes (per WHO definitions) are randomized to receive either CPX-351 (Study Arm 
A) or cytarabine + daunorubicin (7+3 regimen) (Study Arm B).  Patients are stratified by age and AML 




Age Age 60-69 years 
OR 
Age 70-75 
AML Type • Therapy-related AML: t-AML 
• MDS transformed to AML with prior HMA treatment: MDSAML 
• MDS transformed to AML without prior HMA treatment: MDSAML 
• CMMoL transformed to AML: CMMoLAML 
• De novo AML with MDS karyotype: de novoAML 
 
Study enrollment duration is expected to be approximately 20 months.  Efficacy and safety will be 
compared between the two study arms.  Pharmacokinetic samples, at prespecified timepoints, will be 
collected in every CPX-351 patient. 
Sample Size: 
Two hundred forty (240) patients will be randomized with equal allocation between arms to obtain a 
minimum of 220 evaluable patients: 110 in the CPX-351 arm and 110 in the 7+3 arm. 
Inclusion Criteria: 
• Ability to understand and voluntarily give informed consent 
• Age 60-75 years at the time of diagnosis of AML 
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• Pathological diagnosis of AML according to WHO criteria (with at least 20% blasts in the 
peripheral blood or bone marrow) 
• Confirmation of: 
o Therapy related AML: t-AML must have a documented history of prior cytotoxic therapy 
or ionizing radiotherapy for an unrelated disease 
o AML with a history of myelodysplasia: MDSAML must have bone marrow documentation 
of prior MDS  
o AML with a history of CMMoL: CMMoLAML must have bone marrow documentation of 
prior CMMoL 
o De novo AML with karyotypic abnormalities characteristic of MDS: de novoAML must 
have cytogenetics with abnormalities per WHO. 
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2 
• Able to adhere to the study visit schedule and other protocol requirements 
• Laboratory values fulfilling the following: 
o Serum creatinine < 2.0 mg/dL 
o Serum total bilirubin < 2.0 mg/dL, patients with Gilbert’s Syndrome should contact the 
medical monitor 
o Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note:  
If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor 
to discuss. 
• Cardiac ejection fraction ≥ 50% by echocardiography or MUGA   
• Patients with second malignancies in remission may be eligible if there is clinical evidence of 
disease stability for a period of greater than 6 months off cytotoxic chemotherapy, documented by 
imaging, tumor marker studies, etc., at screening.  Patients maintained on long-term non-
chemotherapy treatment, e.g., hormonal therapy, are eligible. 
 
Exclusion Criteria: 
• Except for CMMoL, patients with history of myeloproliferative neoplasms (MPN) (defined as a 
history of essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis prior to the 
diagnosis of AML) or combined MDS/MPN are not eligible.   
• Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16 if 
known at the time of randomization. 
• Clinical evidence of active CNS leukemia 
• Patients with active (uncontrolled, metastatic) second malignancies are excluded.  
• 5.1.2.5 Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted 
for control of blood counts.  For example, a patient with MDS that changes HMA dose and 
schedule after the diagnosis of AML is excluded.  AML-type therapy, such as cytarabine alone 
(>1g/m2/day) or cytarabine plus an anthracycline as well as prior HSCT are also excluded. 
• Administration of any therapy for MDS (conventional or investigational) must be completed by 2 
weeks prior to of the first dose of study drug; in the event of rapidly proliferative disease use of 
hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated 
with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment. 
• Any major surgery or radiation therapy within four weeks.  
• Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or 
equivalent). 
• Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent 
obtaining informed consent 
• Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, 
significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting 
in heart failure by New York Heart Association Criteria (Class III or IV staging) 
• Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, 
antifungal or antiviral treatment) may be entered into the study but must be afebrile and 
hemodynamically stable for ≥72 hrs. 
• Current evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal 
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infection must have a subsequent negative cultures to be eligible; known HIV (new testing not 
required) or evidence of active hepatitis B or C infection (with rising transaminase values) 
• Hypersensitivity to cytarabine, daunorubicin or liposomal products 
• History of Wilson’s disease or other copper-metabolism disorder 
 
Study Drug: 
CPX-351 (cytarabine:daunorubicin) Liposome Injection is a liposomal formulation of a fixed combination 
of the antineoplastic drugs cytarabine and daunorubicin.  The two drugs are present inside the liposome in a 
5:1 molar ratio shown to act synergistically in pre-clinical studies.  The liposome membrane is composed 
of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.  
 
CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials.  
Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL).  Each unit (u) contains 1.0 




Arm A (CPX-351): Study drug will be given intravenously at 100u/m2 on days 1, 3 and 5 by 
approximately 90 minute infusion. 
Arm B (7+3): Therapy will be administered intravenously with 100mg/m2/day of cytarabine administered 
by continuous infusion for 7 days and 60mg/m2 of daunorubicin given on days 1, 2 and 3.  
2nd Induction 
A second induction is highly recommended for any patient with documented reduction in leukemia burden 
and is mandatory for patients achieving >50% reduction in % blasts count on the Day 14 bone marrow 
assessment.  In case the Day 14 bone marrow is non-evaluable or assessment of a morphologic leukemia-
free state is equivocal, a repeat evaluation may be performed 5-10 days later, at the discretion of the 
treating physician, in order to determine effect and need for second induction. Patients who are not 
expected to receive second inductions include all patients with evidence of aplasia/hypoplasia (<5% blast 
count) and patients with equivocal bone marrow results who will have marrow exam repeated.  Patients 
unable to achieve a response (CR+CRi) after two inductions are discontinued from the treatment period 
and followed for survival. 
 
The second induction uses a modified dose and schedule: 
Arm A (CPX-351): Study drug will be given intravenously at 100u/m2 on days 1 and 3 by approximately 
90 minute infusion. 
Arm B (5+2): Therapy will be administered intravenously with 100mg/m2/day of cytarabine administered 
by continuous infusion for 5 days and 60mg/m2 of daunorubicin given on days 1 and 2. 
Consolidation(s) 
Only patients with documented response (CR or CRi) are eligible for chemotherapy consolidation.  Prior to 
the first chemotherapy consolidation the LVEF must be documented to be ≥50% and prior to every 
consolidation the PS must be 0-2. A second consolidation course may be given if the first consolidation 
was well tolerated.  Consolidation with stem cell transplant (HSCT) is permitted either in place of 
chemotherapy consolidation or following chemotherapy consolidation.  Consolidation therapy is highly 
recommended for every patient achieving CR or CRi.    First consolidation must be given no earlier than 35 
days after the start of the last induction and no later than 75 days after the start of the last induction. 
Patients must have recovered to ANC >500/ μL and platelets >50,000/μL to be eligible for first or second 
consolidation.  The second consolidation is administered 35-56 days after the start of the first 
consolidation. 
 
Consolidation Dosing  
Arm A:  CPX-351  
65 u/m2 90 min infusion on Days 1 and 3 
Arm B:  5+2 
Cytarabine 100mg/m2 Continuous Infusion Days 1-5  
Daunorubicin 60 mg/m2 IV Days 1 and 2 
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Follow-up 
Patients will be followed until death or up to 5 years following randomization.  For Event-free Survival 
(EFS) evaluation, an event is documented as persistent AML after induction or relapse after achievement of 
CR/CRi or death.  After documentation of persistent leukemia or relapse, follow-up for overall survival 
continues. At the start of HSCT or non-protocol consolidation treatment, AE data collection stops.   
Efficacy Variables & Analysis: 
• Primary endpoint:  
o Overall Survival (OS)  
• Secondary endpoints:  
o Rate of morphologic leukemia-free state 
o Response rate (CR+CRi), (morphologic, cytogenetic and molecular response) 
o Remission duration (relapse-free survival) 
o Event Free Survival 
Safety Variables & Analysis: 
Patients will be monitored for all clinical adverse events as well as laboratory evaluations. 
• Induction Mortality:  Day 30 and 60 
• Serious Adverse Events 
• Adverse Events: Grades 1-5 and Grades 3-5 
• Laboratory Evaluations 
o Shift table analyses for hematology and chemistries 
o Time to hematologic recovery and proportion with prolonged cytopenias (≥ 56 days) 
o Copper levels: time to return to baseline levels 
• Cardiac Evaluations 
o Cardiac AEs: Grades 1-5 and Grades 3-5 
o ECG changes (pre and post treatment) 
o LVEF changes (pre and post treatment) 
Other Variables & Analysis: 
PK Sampling for population PK:  Patients randomized to CPX-351 are to have samples drawn for 
population PK.  Four samples per patient are taken during the first induction course.  CPX-351 patients will 
be sub-randomized to one of two PK sampling schedules:  Schedule 1  Day 1: 45 min, 3 hrs, 8 hrs and prior 
to dosing on Day 3 (48 hrs (+/- 6 hrs)) or Schedule 2: Day 1: End of Infusion, 2 hrs, 6 hrs and prior to 
dosing on Day 5 (96 hr (+/- 6 hrs)).  The exact time and date of drug administration and of the PK samples 
will be documented in the CRF. 
Serum Copper Sampling:  All patients, including those in the control arm, will have serum copper levels 
assessed at baseline prior to the first dose, after the last induction and at Day 150.  The data will be used to 
assess the variability of serum copper levels in the population as a whole and to determine the proportion of 
patients with persistently elevated serum copper levels after the end of treatment with CPX-351.  Patients 
with elevated serum copper levels (>20% above upper limit of normal) at Day 150 will have monthly 
serum copper determinations until 1 year from randomization or documentation of return of serum copper 
to normal levels. 
Medical Resource Use:  All patients will be assessed for causes and duration of hospitalization.  
Hospitalization duration associated with first induction, second induction, all inductions, first 
consolidation, and all consolidations will be assessed.  The number of nights and percentage of nights spent 
in hospital on general wards vs. intensive care settings will be compared as well as duration of 
hospitalization associated with CR, CRi, and persistent AML.  Cumulative hospitalization of Arm A vs. 
Arm B will be assessed.  Similar assessments will be made for red blood cell transfusions, platelet 
transfusions and supportive care medications (e.g. antibiotics, anti-fungals, anti-virals and growth factors). 
 
Independent Assessments: 
Central Review of Diagnosis/Response: 
• Review of hematopathology reports documenting diagnosis of AML, prior AHD and/or 
chemotherapy exposure 
• FISH or cytogenetics reports documenting karyotypic abnormalities characteristic of 
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myelodysplasia.   
• Review of hematopathology and peripheral blood reports documenting response. 
• A charter will be reviewed and ratified prior to the initiation of the study 
Data and Safety Monitoring Board: 
• Consists of at least 2 hematologists + 1 cardiologist + 1 statistician  
• Hold at least five meetings: Before the study starts, at 25%, 50%, 75% of accrued patients and end 
of study to review day 60 deaths and SAEs 
• A single assessment of early deaths will be conducted after 60 patients (30 per arm) have been 
accrued and followed for 60 days. 
• Study stops if the 60 day death rate in either arm is unacceptable as determined by the DSMB 
using pre-defined early stopping rules. 
• A charter will be reviewed and ratified prior to the initiation of the study 
Cardiac Assessments: 
• All assessments will be obtained and read locally for patient care. ECHO/MUGA scans will be 
sent to a central cardiac vendor who will archive the scans for review at a later date. Details will 
be provided in the cardiac vendor’s manual.  
 
Supportive care: 
Infection Prophylaxis:  is highly recommended during the period of profound neutropenia until ANC 
returns to 500 or greater. The choice of anti-infectives will be according to institutional protocol. 
Growth Factor support: The use of growth factors will be according to institutional protocol. 
Transfusion support:  The use of transfusion support will be according to institutional protocol. 
Statistical Analysis: 
This is a randomized phase III study with equal allocation to each of the two treatments, CPX-351 (arm A) 
and standard of care (7+3, arm B). A total of 220 evaluable patients (110 patients per arm) will be enrolled 
in this study. Furthermore, we anticipate an accrual rate of 135 evaluable patients per year. An additional 
20 patients (10 in each arm) will be accrued to account for ineligibilities and withdrawal of consent.  
Primary Endpoint: The primary objective of this study is to compare overall survival (OS), as defined in 
section 8.2, in all randomized patients. A median OS of 6 months is anticipated in the control arm (Arm B). 
Assuming exponential survival, 110 patients per arm results in a study with 94% power and a one-sided 
significance level alpha of 0.025 to detect a hazard ratio of 0.60 between the two treatment arms. The 
analysis for the primary endpoint will be performed after 190 deaths (86%) have occurred. Assuming 
exponential survival, uniform recruitment of 135 eligible patients per year, 1.65 years of accrual and 1.2 
years of follow-up and a median overall survival of 6 months, 190 events are expected to occur within 2.85 
years after the opening of the study.  
Population PK:  Plasma samples for population pharmacokinetic (PK) assessment will be analyzed for 
concentrations of cytarabine and daunorubicin and their associated metabolites following CPX-351 
adminstration.  A population PK modeling approach will be used to describe plasma concentrations for 
each analyte.  In the analysis, a number of covariates, including age, weight, gender, and concomitant 
medications, will be evaluated to determine if they contribute to differences in the PK estimates among 
individuals.  Details of the analysis will be described in a separate population PK analysis plan 
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ABBREVIATIONS 
7+3 Seven days of continuous infusion of cytarabine at 100 mg/m2/day and 
three days of daunorubicin at 60 mg/m2/day 
5+2 Five days of continuous infusion of cytarabine at 100 mg/m2/day and 2 
days of daunorubicin at 60 mg/m2/day 
ADR  Adverse Drug Reaction 
AE  Adverse Event 
AHD  Antecedent Hematologic Disorders 
ALL  Acute Lymphocytic Leukemia 
ALT  Alanine Transaminase (SGPT) 
AML  Acute Myeloid Leukemia 
ANC  Absolute Neutrophil Count 
Ara-U  Arabinosyluracil 
ASCO  American Society of Clinical Oncology 
AST  Aspartate Transaminase (SGOT) 
ATPase Adenosine triphosphatase 
AUC  Area under the plasma concentration-time curve 
BSA  Body Surface Area 
BUN  Blood Urea Nitrogen 
C  Celsius 
Cmax  Maximum plasma concentration 
CL  Clearance 
CNS  Central nervous system 
CPX-351 CPX-351 (cytarabine:daunorubicin) Liposome Injection 
CR  Complete Response 
CRi  Complete Response with incomplete hematologic recovery 
CRF  Case Report Form 
CMMoL Chronic Myelomonocytic Leukemia 
CTCAE Common Terminology Criteria for Adverse Events 
d  day 
DEHP  di(2-ethylhexyl)phthalate 
dL  deciliter 
DSMB  Data and Safety Monitoring Board 
DSPG  Distearoylphosphatidylglycerol 
DSPC  Distearoylphosphatidylcholine 
EC  Ethics Committee 
ECG  Electrocardiogram 
ECOG  Eastern Cooperative Oncology Group 
EFS  Event-free Survival 
ELN  European LeukemiaNet 
EOI  End of Infusion 
EU  European Union 
FDA  Food and Drug Administration 
FISH  Fluorescence in situ Hybridization 
g  gram(s) 
GCP  Good Clinical Practice 
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HCl  Hydrogen Chloride 
HIPAA Health Information Protection and Portability Act 
HIV  Human Immunodeficiency Virus 
HMA  Hypomethylating Agent 
HOVON Hemato-Oncologie voor Volwassenen Nederland 
HP  High Purity 
HSCT   Hematopoietic Stem Cell Transplantation 
ICF  Informed Consent Form 
ICH  International Committee on Harmonization 
ITT  Intent-to-treat 
IRB/EC  Institutional Review Board/Ethics Committee 
iv, IV  intravenous 
K-M  Kaplan-Meier 
L  liter 
LDH  Lactate Dehydrogenase 
LVEF  Left ventricular ejection fraction 
m2  square meters 
MDR  Multi-drug Resistance 
MDS  myelodysplastic syndrome 
MedDRA Medical Dictionary for Regulatory Activities 
mg  milligram(s) 
mL  milliliter(s) 
MLL  Mixed Lineage Leukemia 
MPN  Myeloproliferative neoplasm 
MLS  Morphologic Leukemia-free State 
MRU  Medical Resource Usage 
MTD  Maximum Tolerated Dose 
MUGA Multiple Gated Acquisition scan 
mw  molecular weight 
N  Number, Population 
NF  National Formulary 
OS  Overall Survival 
PD  Persistent Disease 
PhEur  European Pharmacopoeia 
PHI  Protected Health Information 
PK  Pharmacokinetics 
PS  Performance Status 
q.s.  quantum sufficiat 
RBC  Red blood cells 
SAE  Serious Adverse Event 
SD  Standard deviation 
sAML  Secondary AML 
T1/2  Half-life 
t-AML  Therapy-related AML 
Tmax  Time of occurrence of Cmax 
u  Units 
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μL  Microliter 
ULN  Upper Limits of Normal 
USP  United States Pharmacopeia 
V  Volume 
WHO  World Health Organization 
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1.0 General Information 
This document is a protocol for a human research study. This study is to be conducted 
according to United States and international standards of Good Clinical Practice (FDA 
Title 21 parts 11, 50, 54, 56, 312, International Conference on Harmonization and the 
Declaration of Helsinki), applicable government regulations and Institutional research 
policies and procedures. 
2.0 Background Information 
2.1 Acute Myeloid Leukemia in the Elderly and its Treatment 
Acute myeloid leukemia represents a group of clonal hematopoietic stem cell disorders in 
which both failure to differentiate and excessive proliferation in the stem cell 
compartment result in accumulation of non-functional cells termed myeloblasts.2 
 
Untreated AML in all ages is rapidly fatal, with patients dying on average within a few 
months of diagnosis.  Even with treatment, particular groups of AML patients continue to 
have a poor prognosis.  AML in the elderly (age ≥60) is associated with increased risk of 
not responding to therapy and increased risk of dying from the treatment.  Appelbaum, et 
al.3 and Kantarjian, et al.4 summarize the factors that contribute to poor outcomes in 
elderly patients with AML. Risk factors that decrease patient tolerance to therapy or 
sensitivity of the leukemia to therapy include increasing age, poor performance status, co-
morbid medical conditions, accumulated chromosomal abnormalities, adverse mutations, 
and multi-drug resistance. 
 
There is broad overlap of these risk factors with most elderly AML patients having one or 
more adverse features.  The poor results of treatment in elderly AML lead to a reluctance 
to treat elderly patients with intensive regimens designed to induce aplasia and complete 
remission. 
 
Clearing the marrow of leukemia has historically been the only means of obtaining 
prolonged survival in AML patients.  This is usually accomplished by use of intensive 
cytotoxic/cytoreductive therapy.5  The intensity of treatment needed to induce aplasia and 
complete remission is associated with early mortality rates of 10-20% in elderly patients 
considered fit for intensive therapy and is higher in patients with co-morbidities and poor 
performance status.3,4,6-8 
 
Burnett, et al. 9 published a study of 1273 fit elderly AML patients given intensive 
therapy.  This trial identified cytogenetics, presenting white blood count, age and 
secondary AML as the main predictors of outcome.  Clinical outcomes did not improve 
with: intensification of induction therapy (daunorubicin 50 mg/m2 versus 35 mg/m2 and 
cytarabine 400 mg/m2 versus 200 mg/m2), increasing the duration of consolidation from 
three to four courses, or use of an MDR modulator (PSC-833). 
 
A randomized study reported in 2009 showed that a double induction regimen with 90 
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intermediate dose cytarabine (1 g/m2) could be safely administered with high rates of 
complete remission in older patients. The second induction was given even to those who 
had already achieved CR after first induction, a practice that is not routinely used in the 
US and Canada.  This publication from the HOVON group noted improvement in 
remission rate when compared to a cytarabine plus 45 mg/m2 daunorubicin regimen but 
no improvement in disease-free survival or overall survival was observed.10  At the 
present time, the HOVON study has not been replicated in elderly patients by any other 
group.  
 
Another study by Fernandez, et al., reported success for the same 90 mg/m2 daunorubicin 
dose versus 45 mg/m2 when used for first induction for younger patients.11 If a patient 
required a second induction, the dose of daunorubicin was reduced to 45 mg/m2 for all 
patients.  Responding patients were taken to transplant.  Neither this study nor the 
HOVON study used daunorubicin 90 mg/m2 for second induction courses or in 
consolidation and neither study demonstrated that 90 mg/m2 is more effective than 60 
mg/m2.  Although of great interest, neither regimen is ready to be used as the control arm 
in a comparative study with CPX-351. 
 
The 7+3 regimen using 60 mg/m2 daunorubicin has been, and continues to be, widely 
used in the U.S., Canada and the European Union and is supported by a large body of 
medical literature.  Variations on the 7+3 regimen using different anthracyclines, 
different doses, and different schedules of cytarabine and daunorubicin all lead to the 
conclusion that this regimen remains acceptable as standard of care for older patients able 
to tolerate intensive chemotherapy. 
 
The control regimen for this pivotal study with CPX-351 is the 7+3 regimen using 100 
mg/m2/d cytarabine by continuous infusion for 7 days and 60 mg/m2 of daunorubicin on 
days 1, 2, and 3.  Celator proposes daunorubicin as the control anthracycline because that 
allows a direct comparison of CPX-351 which also delivers daunorubicin.  In addition, 
because both study arms receive cytarabine and daunorubicin this study will be a direct 
test of whether molar ratio controlled drug delivery can improve antitumor efficacy.  
Celator also proposes that post-remission chemotherapy be as symmetrical as possible in 
both arms of the study and plans to reduce the intensity of consolidation with CPX-351 
(reduced from 3 to 2 doses and from 100 units/m2 to 65 units/m2 ) to match that of control 
(7+3 reduced to 5+2). These adjustments in post remission therapy with CPX-351 are 
intended to result in similar levels of myelosuppresion during consolidation therapy.  
 
After complete remission is achieved, leukemic cells likely remain in numbers too small 
to be detected with current diagnostic techniques. If no further post remission or 
consolidation therapy is given, almost all patients will eventually relapse.12  Therefore, 
post-remission therapy is necessary to eliminate non-detectable disease and prevent or 
delay relapse.  The best consolidation regimen has never been well defined.  Generally, 
the intensity of the standard 7+3 induction therapy is reduced to “5+2” for consolidation, 
which is a five day continuous infusion of the same dose of cytarabine given during 
induction and two instead of three days of the anthracycline.  Retaining cytarabine and 















IND 72,939 PROTOCOL CLTR0310-301 
CPX-351 (cytarabine:daunorubicin) Liposome Injection May 22, 2012, Version 1.0 
 
CONFIDENTIAL Page 16 of 69  
CELATOR PHARMACEUTICALS, INC. 
the active antileukemia therapies restricted to cytarabine and daunorubicin in both arms 
allows a better test of the hypothesis that ratiometric dosing explains the difference in 
observed efficacy and safety. 
 
For patients at high risk of relapse (e.g. those with high-risk cytogenetics, antecedent 
hematologic disorder, or therapy-related AML), allogeneic stem cell transplantation 
(HSCT) is usually recommended if the patient is able to tolerate a transplant and has a 
suitable donor.  This form of post remission therapy must be permitted for all patients on 
this study because its use as post remission therapy is associated with prolonged relapse 
free survival.  Because of potential imbalances in use of HSCT, a formal sensitivity 
analysis will be performed in addition to an intent to treat analysis.  The sensitivity 
analysis is performed by re-analyzing the data after censoring patients at the start of 
HSCT, so that survival potentially attributable to HSCT can be removed, isolating the 
contribution of study treatment. 
 
Secondary AML is a term that has been used to cover a heterogeneous group of poor 
prognosis AML arising in a setting of prior treatment with cytotoxic agents or large field 
radiation therapy and/or antecedent hematologic disorders (AHD).  At the chromosomal 
level, specific karyotypic abnormalities have been identified and linked to 
myelodysplasia.  As a consequence, the term secondary AML is somewhat ambiguous 
and for the purposes of this trial, has been supplemented with specific WHO-based 
definitions of particular patient groups that have usually been grouped under the umbrella 
of secondary AML.  This study is open to some but not all patient subsets grouped within 
secondary AML.  Specifically included are patients with treatment-related AML, those 
with documented pre-existing myelodysplasia and CMMoL, and patients with de novo 
AML with specific chromosomal abnormalities linked to myelodysplasia per WHO 
criteria.  Excluded are patients with MPN (except for CMMoL), MDS/MPN, and patients 
with multilineage dysplasia (per WHO) in the absence of a history of MDS or specific 
MDS-related cytogenetic abnormalities.  The grounds for these exclusions are based on 
differences in the prognosis of these patient subsets, with low probability of response and 
poor survival among MPN and MDS/MPN patients and higher probability of response 
and survival among patients with multilineage dysplasia only.  After excluding these 
patient subsets, the remaining patients still have high risk disease but have relatively 
similar prognosis.  Patients eligible for this study continue to have poorer response rate, 
shorter duration of remission, and shorter overall survival than good risk de novo AML 
patients.13  If patient entry in the Phase II study in newly diagnosed patients (Study 204) 
is a guide to probable future patient accrual, the proportion of patients with high risk 
characteristics as defined above is 68/126 (54%) and after exclusion of patients with 
MPN or MDS/MPN is 58/126 patients (46%), suggesting that this study may access 
nearly half of all patients with AML in the 60-75 year age range and the majority (~65%) 
of patients with high risk AML. 
 
Identifying patients with de novo AML eligible on the basis of cytogenetics will require 
waiting for the results of cytogenetics testing or performing a panel of FISH-based 
assays.  Celator will make available a reference laboratory to perform cytogenetic assays 















IND 72,939 PROTOCOL CLTR0310-301 
CPX-351 (cytarabine:daunorubicin) Liposome Injection May 22, 2012, Version 1.0 
 
CONFIDENTIAL Page 17 of 69  
CELATOR PHARMACEUTICALS, INC. 
is understood that rapid initiation of treatment is preferred and that delaying onset of 
treatment for 2-3 days beyond the initial work-up will be uncomfortable for patients and 
physicians alike.  A review of the recent literature reveals that in a series of 1317 patients 
gathered from Cleveland Clinic and MD Anderson Hospitals14 longer time from 
diagnosis to treatment was not a significant factor in worsening rate of CR(p=0.63) or 
reducing OS (p=0.30) in older patients.  The authors concluded that delaying treatment 
did not seem harmful in older patients and patients may benefit from waiting for 
additional testing to return, allowing enrollment into studies that account for cytogenetic 
findings. 
 
2.2 CombiPlex® Technology 
In vitro studies have shown that antitumor activity can be enhanced when cytotoxic drugs 
are used in combination.  This has led, over the years, to the use of drug combinations in 
the clinic such that cytotoxic drug combinations are now standard in many forms of 
cancer treatment.  New anticancer drugs are typically first introduced in patients as single 
agents.  After a maximum tolerated dose is determined for one agent, a second agent is 
added and the dose of one or both agents is adjusted on the basis of toxicity.  The 
development of these combination regimens then is determined empirically on the basis 
of tolerability.  However, in vitro, where the ratio of drugs used in combination can be 
controlled, it has been demonstrated that drug combinations providing synergy at one 
ratio may be simply additive or even antagonistic at other ratios.15  When individual free 
drugs are administered, each agent is handled differently by the body, resulting in varying 
distribution of the individual drugs to tumor sites which can result in drug ratios that are 
suboptimal or ineffective.  Celator’s technology is based on the findings that in vitro 
synergistic activity of antineoplastic drugs depends on specific drug ratios and that the in 
vivo activity of a combination depends on maintaining the synergistic ratio.  In this way, 
the development of a particular chemotherapeutic regimen can be based on the most 
efficacious ratio rather than empirically based on toxicity. 
 
The development of CPX-351 (cytarabine:daunorubicin) Liposome Injection was based 
on 1) defining a synergistic ratio of the two active moieties, cytarabine and daunorubicin, 
using cell-based screening assays and 2) designing a liposomal drug carrier to maintain 
this ratio after intravenous administration.  This ratio was not based on the empirically-
derived, toxicity-guided regimens currently used for cytarabine and anthracyclines. 
 
2.3 Physical, Chemical and Pharmaceutical Information 
CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs 
cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 
molar ratio.  The liposome membrane is composed of distearoylphosphatidylcholine, 
distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.  These liposomes 
have a nominal diameter of approximately 100nm and are suspended in sucrose.  
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CPX-351 is provided as a sterile, pyrogen-free lyophilized formulation in 50 mL glass, 
single-use vials.  Each vial contains 100 units of CPX-351 where each unit contains 1.0 
mg cytarabine and 0.44 mg daunorubicin base in liposomes.  The lyophilized cake is 
reconstituted with sterile water for injection to obtain a homogeneous dispersion at 5 
units/mL.  The composition of the formulation after reconstitution is listed in Table 1 
below. 
 







Cytarabine, USP/PhEur 243 100 mg 1.0 mg 
Daunorubicin HCl USP/ PhEur (reported as the free base) 528 44 mg 0.44 mg 
Distearoylphosphatidylcholine 790 454 mg 4.5 mg 
Distearoylphosphatidylglycerol 801 132 mg 1.3 mg 
Cholesterol, HP 387 32 mg 0.3 mg 
Copper gluconate, USP 454 92 mg 0.9 mg 
Triethanolamine, NF 149 7 mg 0.07 mg 
Sucrose, NF 342 2054 mg 20.54 mg 
 
2.4 Product Label 
CPX-351 (cytarabine:daunorubicin) LIPOSOME FOR INJECTION  100 units/Vial 
Each unit contains 1.0 mg (±10%) Cytarabine and 0.44 mg (±10%) Daunorubicin (base) in liposomes 
containing DSPC, DSPG and cholesterol.  Also contains copper as copper gluconate, triethanolamine and 
sucrose. 
Store refrigerated at 5°C (±3°C) in an upright position. 
FRAGILE: Do not drop 
Caution: New Drug – Limited by Federal Law to Investigational Use 
Manufactured for 
Celator Pharmaceuticals, Inc.,  
Lot #______________   Expiration Date:_________________ 
 
2.5 Pre-clinical Pharmacology & Toxicology 
The pre-clinical pharmacology and toxicology are summarized in the Investigator’s 
Brochure for CPX-351. 
 
2.6 Brief Summary of Prior Clinical Studies 
Three clinical studies have been completed with CPX-351 and a detailed presentation is 
available in the Investigator’s Brochure.  A brief summary of these studies is presented 
below. 
 
2.6.1 Phase I Study of CPX-351: CLTR0305-101 
The primary goal for this study was to establish the MTD for CPX-351 and recommend a 
dose for further study in a Phase II setting.  Pharmacokinetic assessments were made at 
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The dosage regimen was designed to mimic the 7-day drug exposure provided by 
conventional 7+3 treatment using a single induction course administering doses on Days 
1, 3, and 5, by 90 minute infusion.  Patients with AML (multiply relapsed, refractory, or 
with first CR duration of 6 months or less), ALL, and high risk MDS were eligible. 
 
Dose limiting toxicities were observed at the 10th dose level: 134 u/m2 (134 mg/m2 
cytarabine + 59 mg/m2 daunorubicin).  One patient had significant reduction in post 
treatment LVEF and as a result the Phase II studies included a cap (500 mg/m2) on 
cumulative anthracycline dose after one induction course of CPX-351 and patients with 
significant pre-existing cardiac disease were excluded.  Other dose-limiting toxicities 
included hypertensive crisis and prolonged (>56 days) cytopenias. 
 
The Phase I study of CPX-351 assessed the concentrations of cytarabine, daunorubicin, 
uracil arabinoside, and daunorubicinol at multiple dose levels and found that they 
exhibited mono-exponential, first order elimination with minimal early phase 
distribution. 
 
The day 1 (single dose) and day 5 (multiple dose) Cmax and AUC(0-τ) were linear and the 
5:1 molar ratio of cytarabine to daunorubicin was maintained for up to 24 hours after 
dosing at all dose levels on days 1 and 5. 
 
CPX-351 was found to have markedly prolonged mean half life for both cytarabine and 
daunorubicin, greater drug exposure (AUC), and higher peak plasma concentrations 
(Cmax).  Measurable drug levels were present seven days after the last infusion of CPX-
351 (Study Day 12).   
 
Response was observed in 1 of 3 multiply relapsed ALL and 10 of 43 AML patients. This 
was notable because most of the AML patients had already received cytarabine and 
daunorubicin in the past. 
 
The maximally tolerated dose (101 u/m2) was defined and persistence of the 5:1 molar 
ratio for up to 24 hours in the plasma was confirmed. Multiple responses in previously 
treated AML patients confirmed antileukemic activity. 
2.6.2 Phase II Study of CPX-351: CLTR0308-204 
The 204 study was designed as a randomized study comparing CPX-351 head-to-head 
against 7+3, in newly diagnosed, older (age 60-75) patients with AML.  The comparison 
of encapsulated cytarabine and daunorubicin (CPX-351) versus free cytarabine and 
daunorubicin (7+3) would be fully interpretable for relative efficacy and safety. One 
hundred twenty-seven patients were randomized 2:1 to receive CPX-351 or 7+3. 
Response rate (CR+CRi) was the primary endpoint and superior response with a one-
sided p-value of <0.1 was deemed sufficient for moving forward in development. 
Secondary endpoints were overall survival, event-free survival, CR+CRi duration, % 
leukemia-free after induction, safety and practicality of CPX-351 as consolidation 
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CPX-351 100 u/m2 IV days 1, 3, 5* 
(80 pts)
“7+3” Regimen* 
Cytarabine 100 mg/m2 7-day infusion 
Daunorubicin 60 mg/m2 days 1, 2, 3 
 (40 pts)
Two arms, n=120 patients• Newly diagnosed AML 
• Age 60- 75 years 
• Able to tolerate intensive 
chemotherapy 
• High-risk and standard-risk based 
on age, karyotype and AML type 
• PS 0-2 
*Up to 2 inductions/ 2 consolidations 
 
At entry patients were stratified by age (60-69 vs. 70-75), cytogenetics (< or ≥3 
cytogenetic abnormalities), and type of AML (de novo vs. secondary).  High risk patients 
were older (age 70 to <76) or had complex cytogenetics (≥3 cytogenetic abnormalities) or 
had secondary AML.  Standard risk patients were younger (age 60-69), had non-complex 
cytogenetics (<3 abnormalities) and had de novo AML.  After accrual was complete,  
reviewed all of the cytogenetic 
reports and confirmed/corrected assignment of patients to <3 or ≥3 cytogenetic 
abnormalities and provided assessment of favorable, intermediate, and adverse 
cytogenetics per NCCN guidelines.  Randomization and stratification were successful in 
balancing demographic and leukemia associated risk factors between the two study arms.   
 
CPX-351 produced superior rates of leukemic-free state and response with similar 
duration of remission.  It was notable that the improvement in response occurred 
predominately in the form of CRi (CR with incomplete hematologic recovery). 
 
The study met the primary endpoint with a response rate of 66.7% compared to 51.2% 
with a p-value of 0.0712.  Further analysis of response according to the stratification 
factors demonstrated consistent benefit for CPX-351 in response rate across every 
subgroup. 
 
Kaplan-Meier (K-M) analysis after a minimum follow up of 1-year demonstrated non-
significant improvements for CPX-351 for Event Free Survival (EFS) and Overall 
Survival (OS) in the overall population and the high risk strata. 
 
Induction mortality was assessed at Day 30 and 60.  A lower rate of early mortality was 
observed for CPX-351 treated patients at 60 days (4/85, 4.7% vs. 6/41, 14.6%, p=0.053).  
This result is the best evidence that CPX-351 treatment is acceptably safe and suggests 
that rapid clearance of leukemia may assist in reducing the early death rate. 
 
CPX-351 treatment was associated with greater myelosuppression and more prolonged 
cytopenias, higher frequency of febrile neutropenia (63.5% vs. 51.2%), infections (e.g. 
bacteremia (42.4% vs. 22%)), and bleeding events (e.g. epistaxis (36.5% vs. 19.5%)).  
Otherwise, adverse events were qualitatively similar between both study arms.  The lower 
mortality rate at 30 and 60 days indicates that CPX-351 was safe in spite of the 
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Observations of reduced early mortality and a significant survival advantage (HR=0.41, 
p=0.02) among secondary AML patients suggest that clinical benefit is likely for this 
patient group in Phase III. 
 
2.6.3 Phase II Study of CPX-351: CLTR0308-205 
This study compared CPX-351 (100u/m2; Day 1, 3, 5) with salvage therapy in first 
relapse AML patients.  This trial planned to accrue 120 patients with a 2:1 randomization 
to CPX-351 or investigator’s choice of first salvage treatment.  Responding patients were 
expected to receive allogeneic stem cell transplant for consolidation if donors were 
available.  The European Prognostic Index was used to stratify patients.  The primary 
endpoint was survival at one year, which was expected to be approximately 30% based 
on the literature.  Secondary endpoints were CR+CRi rate, remission duration, event-free 
survival and 30/60/90 day mortality. 
 
CPX-351 was able to increase the rate of leukemia-free state (77% vs. 60%), CR + CRi 
rate (49% vs. 41%), and had comparable 60-day mortality (15% vs. 16%), and better 90-
day mortality (19% vs. 30%).  After 1-year of follow up there were trends favoring CPX-
351 for event free survival (HR=0.66, p=0.08) and overall survival (HR=0.75, p=0.19) 
among all patients and a subset analysis of the unfavorable risk group by European 
Prognostic Index showed a significant improvement in overall survival (HR=0.55, 
p=0.02).  The proportion of CPX-351 patients alive at 1-year was 37% vs. 30% for 
control, and the proportion of unfavorable risk patients alive was 30% vs. 10%.  These 
results in younger (age 18-65) patients with first relapse AML demonstrate potential 
efficacy among all patient subgroups with the largest improvement noted among higher 
risk patients and are entirely consistent with the results from newly diagnosed older 
patients in Study 204.   
 
In summary, data from the Phase I and both randomized Phase II studies demonstrate 
consistent high level activity in AML marked by measurable increases in leukemia-free 
state and clinical response (CR + CRi) in most risk groups when compared to 
conventional therapy.  The greatest relative difference occurred in the highest risk groups 
in both Phase II studies.  The accumulated data suggest that CPX-351 may be a suitable 
replacement for the 7+3 regimen as first-line treatment and may be a useful alternative to 
current salvage regimens in the second-line setting.  The proposed Phase III study is 
designed to confirm improved survival in newly diagnosed AML patients at high risk of 
poor outcome because of antecedent hematologic disorder (e.g. MDS and CMMoL), prior 
cytotoxic treatment (T-AML), and chromosomal abnormalities specifically linked to 
myelodysplasia (per WHO criteria) in patients with apparently de novo AML 
 
2.6.4 Copper Background 
Copper is an essential element that is a component of a number of metalloenzymes acting 
as oxidases (e.g. diamine oxidase, monoamine oxidase, cytochrome c oxidase).  The 
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tolerable Upper Intake Level for adults is 10 mg/day.  A CPX-351 dose of 100 u/m2, 
would administer 36 mg of elemental copper to a patient with a BSA of 2.0 m2.Animal 
toxicology data suggest that elevated copper levels generally returned to baseline 1 to 2 
weeks after the last dose.  No toxicity was seen in animal studies attributable to copper.   
The data from the clinical studies are consistent with the preclinical findings.  Since 
CPX-351 contains copper (0.18 mg copper per unit, in the form of copper gluconate), 
serum total copper levels were monitored in the Phase I clinical study.  
 
Copper levels in patients receiving 3 doses of CPX-351 at 101 u/m2 were elevated on day 
7 (2 days after the last dose) but returned to normal levels in most patients by day 14.  All 
patients had serum copper levels in the normal range by day 42 after induction.  No acute 
toxicities attributable to copper exposure were observed. 
 
The lack of toxicity observed in animal studies and in clinical studies to date is attributed 
to two factors: (1) most of the copper administered remains encapsulated within the 
liposome for most of the time it is in circulation limiting bioavailability and (2) the 
probability of copper-related toxicity is a function of C (the exposure to bioavailable 
copper) x T (the duration of exposure).  If the exposure to elevated copper levels is 
limited to a few weeks, the risk of acute toxicity is probably low.  Copper handling 
diseases generally require years of exposure to elevated copper levels before the onset of 
symptoms.   
 
In this trial, serum copper levels will be monitored until return to baseline (±20%). 
Copper elimination after CPX-351 is likely via biliary excretion and elimination in the 
feces.  It is expected that eligible patients with relatively normal liver function and 
unobstructed biliary systems should be able to eliminate the copper administered within a 
few weeks.  Liver function tests will be performed regularly to assess hepatic 
dysfunction, a common manifestation of copper-related toxicity. 
 
3.0 Study Objectives and Rationale 
3.1 Primary Objectives 
• To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in 
elderly patients (60-75 yrs) with high risk (secondary) AML. The primary 
efficacy endpoint will be overall survival. 
• To confirm the safety of CPX-351 
 
3.2 Secondary Objectives 
• To confirm the improvement in rate of leukemia-free state, response (CR+CRi) 
rate, remission duration (relapse-free survival), event-free survival and overall 
best response (CR+CRi) rate following CPX-351 
• To confirm the safety and practicality of CPX-351 as consolidation therapy 
• To assess serum copper elevations 
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• To assess and compare Pharmacoeconomic differences between CPX-351 and 
control 
 
3.3 Study Rationale 
The Phase I study demonstrated that an MTD in leukemia patients could be established 
for CPX-351 and that the intended 5:1 molar ratio of cytarabine to daunorubicin was 
maintained across multiple dose levels with markedly prolonged plasma half life of 
cytarabine and daunorubicin.  At the MTD, CPX-351 was detectable in plasma at least 7 
days after the last dose (Study Day 12).  A substantial number of responses were 
observed in a population of patients with relapsed and refractory acute leukemia.  This 
was notable because the majority had already received cytarabine and daunorubicin in the 
past. Data from this study was sufficient to give rise to two randomized Phase II trials, 
the first in newly diagnosed elderly AML patients (Study 204) and the second in first 
relapse patients age 18-65 (Study 205).  Data from Study 204 provides the clinical 
rationale for this Phase III study. 
 
Study 204 demonstrated consistent improvement in achievement of leukemia-free state 
and response (CR+CRi) across every AML subgroup studied.  This included standard 
risk and high risk patients and within every constituent of the high risk group (age ≥70, 
adverse cytogenetics, and secondary AML).  Patient numbers were small in most sub-
groups, but the consistency of the response data is fairly persuasive that response 
differentials observed favoring CPX-351 are likely real. 
 
As with response, CPX-351 appeared to improve event free survival across multiple 
subgroups although none were statistically significant. Analyses of the secondary AML 
subset indicated that this group of patients did particularly well relative to control by all 
efficacy and safety parameters.  There were 52 patients with secondary AML by history, 
33 randomized to CPX-351 and 19 randomized to 7+3.  CPX-351 was superior for 
inducing a leukemia-free state (81.3% vs. 57.9%) and CR+CRi rate (57.6% vs. 31.6%), 
K-M analysis of event-free survival after 12 months minimum follow-up showed a 
significant difference in the CPX-351 arm (HR=0.51, p=0.04) and a significant difference 
in overall survival (HR=0.40, p=0.01). 
Figure 1: Study 204: Event-free and Overall Survival in Secondary AML 
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Logrank p-value =0.01 HR=0.40 
 
When 30-day and 60-day mortality rates are assessed, CPX-351 is superior at 30-days 
(3.1% vs. 15.8%) and 60-days (6.1% vs. 31.6%) providing very strong evidence of 
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The unexpected survival advantage in small numbers of secondary AML patients suggest 
a potential clinical benefit in this particular subgroup of patients that has traditionally had 
poor outcome after conventional intensive treatment with median survival duration of 
approximately 6 months.  The study hypothesis is that CPX-351 will improve overall 
survival in newly diagnosed patients with selected antecedent hematologic disorders 
transformed to AML and in de novo AML patients with specific chromosomal 
abnormalities linked with myelodysplasia when compared to conventional 7+3 treatment. 
 
4.0 Study Design 
This study is a randomized, open-label, parallel-arm, standard therapy-controlled Phase 
III trial in patients with selected antecedent hematologic disorders transformed to AML 
(t-AML, MDSAML, and CMMoLAML (with documented history of MDS or CMMoL prior 
to transformation) and de novo AML with karyotypic changes characteristic of 
myelodysplasia, per WHO).  Study enrollment duration is expected to be approximately 
20 months.  On entry, patients are randomized to receive either CPX-351 or standard 
induction treatment with cytarabine and daunorubicin (7+3 regimen).  Patients are 
stratified to balance the likelihood of response and survival between the two arms.  The 
study is designed in 2 phases; the Treatment Phase where patients receive up to two 
induction and two consolidation courses and are intensively monitored for safety (early 
deaths, adverse events, metabolic changes, etc.) and secondary efficacy endpoints 
(CR+CRi rate, rate of HSCT) and a Follow-up Phase, which begins 30-days after the last 
induction or consolidation course and continues for up to 5 years from randomization 
where patients are monitored for the primary (survival) and additional efficacy outcomes 
(event-free survival, best response and response duration).  In addition, pharmacokinetic 
samples, at prespecified timepoints, will be collected from every patient. 
4.1 Stratification 
Patients are stratified to balance these prognostic factors across treatment arms.   
 
Table 2 Definition of Strata: 
Factor Strata 
Age 60-69 vs. 70-75 
AML type Treatment-related AML 
MDSAML with documented history of MDS with prior treatment with hypomethylating agents 
MDSAML with documented history of MDS without prior treatment with hypomethylating agents 
denovoAML with karyotype characteristic of MDS 
CMMoLAML with documented history of CMMoL 
 
4.2 Patient Recruitment 
All patients will be screened by a principal investigator or sub-investigator prior to entry 
on the study.  An explanation of the study and discussion of the expected risks and 
benefits will be fully discussed with patients prior to the screening process in order for 
the patient to provide a voluntary written informed consent.  Only eligible and consenting 
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At screening and prior to obtaining informed consent all prospective patients with newly 
diagnosed AML will have a detailed history of possible exposure to cytotoxic 
chemotherapy and radiation therapy.  Documentation of prior cytotoxic therapy will be 
obtained from discharge summaries, pharmacy records, radiation therapy treatment 
records, etc.  Patients with a history of MDS or CMMoL that has transformed to AML 
will also have documentation (specifically bone marrow examination records) obtained 
confirming the diagnosis and its prior treatment.  Patients with prior treatment are eligible 
but are substratified based on prior treatment with a hypomethylating agent for MDS.  
Finally, patients with apparent de novo AML may still be eligible if they have specific 
chromosomal abnormalities linked to MDS (e.g. complex cytogenetics, -7, -5, etc. See 
APPENDIX 3: WHO Classification of Secondary Acute Myeloid Leukemia18). 
 
4.3 Registration/Randomization Procedures 
After providing informed consent, eligible patients are registered by providing the 
following to the sponsor prior to randomization: 
 
Table 3: Documents Required for Registering a Patient 
 
Patient with a history of: Required Documentation 
MDS/CMMoL • Bone marrow biopsy/aspirate report, including peripheral blood 
smear, documenting MDS/CMMoL diagnosis in the past 
Cytotoxic Chemotherapy • Medical records documenting prior chemotherapy and the condition 
being treated 
• Chemotherapy administration records (preferred) 
• Pharmacy records 
• Other direct evidence of chemotherapy administration  
Ionizing Radiotherapy • Medical records documenting prior radiation therapy, including the 
size of the radiation field, the total dose, and the condition being 
treated  
• Other direct evidence of radiation therapy administration 
Apparent de novo AML • FISH or cytogenetics assay documenting karyotypic abnormalities 
characteristic of myelodysplasia.  Documentation of qualifying 
cytogenetic abnormality must be available prior to registering the 
patient. 
 
Prior to randomization the sponsor must review the documentation and approve the 
patient to be randomized onto the study.  The randomization is done via a telephonic 
or internet-based interactive randomization system.  Specific details and procedures will 
be provided under separate cover.  The system will request information on the patient’s 
age, AML history, MDS/CMMoL history and chemotherapy/radiation history, as well as 
cytogenetics and will confirm eligibility.  After randomization, investigators are 
provided, in writing, the patient number and treatment assignment.  The patients 
pharmacokinetic schedule assignment will also be provided.  The patient number is used 
on all documentation and correspondence. 
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• Treatment center and investigator information 
• Patient’s initials and date of birth 
• Cytogenetics (specific karyotype if it is the sole basis of eligibility or unknown) 
• Disease history: MDS/CMMoL documentation and/or chemotherapy/radiation 
documentation 
 
4.4 Patient Sample Size 
Two-hundred forty (240) patients will be randomized to obtain approximately 220 
evaluable patients.  Equal numbers of patients will be randomized to CPX-351 (Arm A) 
or cytarabine and daunorubicin (Arm B, 7+3). 
 
4.5 Induction 
The initial induction course will begin within 24 hours of randomization.  Following 
randomization, patients are monitored closely for response and safety. Depending on the 
type and extent of response as well as toxicity, the patient may continue on to 
consolidation therapy, receive a second induction, or be discontinued from the Treatment 
Phase and monitored in the Follow-up Phase. 
 
Dosing for first induction: 
• For ARM A:  CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5 
• For ARM B:  7+3: Cytarabine at a dose of 100 mg/m2/day will be administered 
on study days 1-7 via continuous infusion and daunorubicin at a dose of 60 
mg/m2/day will be administered on days 1, 2 and 3. 
 
4.6 Repeat of Induction 
A second induction is highly recommended for any patient with documented reduction in 
leukemia burden and is mandatory for patients achieving >50% reduction in % blasts 
count on the Day 14 bone marrow assessment.  In case the Day 14 bone marrow is non-
evaluable or assessment of a morphologic leukemia-free state is equivocal, a repeat 
evaluation may be performed 5-10 days later, at the discretion of the treating physician, 
in order to determine effect and need for second induction. Patients who are not expected 
to receive second inductions include all patients with evidence of aplasia/hypoplasia 
(<5% blast count) and patients with equivocal bone marrow results who will have 
marrow exam repeated.  Patients unable to achieve a response (CR+CRi) after two 
inductions are discontinued from the treatment period and followed for survival. 
 
Dosing for second induction: 
• For ARM A:  CPX-351 at 100 u/m2 will be administered on days 1 and 3 
• For ARM B:  Cytarabine at a dose of 100 mg/m2/day will be administered on 
days 1-5 and daunorubicin at dose of 60 mg/m2 will be administered on days 1 
and 2 (5+2) 
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4.7 Consolidation Therapy 
Post-remission therapy in older patients with AML produces modest improvement in 
patient outcomes and should be extended to as many patients as possible.  Only patients 
with documented response (CR or CRi) are eligible for consolidation.  The bone marrow 
aspirate/biopsy report and peripheral blood count data is to be made available to the 
sponsor before beginning consolidation.  Prior to the first consolidation the patients 
LVEF must be documented to be ≥50% and prior to every consolidation the patients must 
have a PS of 0-2.  First consolidation must be given no earlier than 35 days after the start 
of the last induction and no later than 75 days after the start of the last induction. Patients 
must have recovered to ANC >500/ μL and platelets >50,000/μL to be eligible for first or 
second consolidation.  The second consolidation is administered 35-56 days after the start 
of the first consolidation. 
Dosing for consolidation: 
• For ARM A:  CPX-351 at 65 u/m2 will be administered on days 1 and 3 
• For ARM B:  Cytarabine at a dose of 100 mg/m2/day will be administered on 
days 1-5 and daunorubicin at dose of 60 mg/m2 will be administered on days 1 
and 2 (5+2) 
 
No other chemotherapy consolidation treatment is permitted.  Only HSCT is permitted in 
place of, or following, chemotherapy consolidation. 
 
4.8 Salvage Therapy 
Patients who never achieve CR/CRi following initial induction and patients who achieve 
CR/CRi and later relapse may receive salvage therapy.   
 
4.9 Follow-up Phase 
The Follow-up Phase consists of routine visits or other patient contact to assess for the 
primary endpoint (survival) and other time to event endpoints (time to relapse). Patients 
enter the follow-up phase at different times depending on their treatment response.  See 
Table 4: 
 
Table 4: Follow-up Phase 
CR Begins after peripheral blood count recovery following the last course of 
treatment (Induction and/or Consolidations)  
CRi Begins after peripheral blood counts recover (to at least ANC to ≥500/μL and 
platelets to ≥50,000/μL) or stabilize after the last course of treatment (Induction 
and/or Consolidations) 
PD/treatment failure Begins 30 days after documentation of persistent AML or discontinuation from 
study therapy if no benefit from further protocol-defined therapy is expected.  The 
30-day period is to document recovery from acute AEs  
Adverse Event Begins 30 days after an AE which, in the opinion of the investigator, requires 
discontinuation of any further protocol therapy.  The 30 days allows for 
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The follow-up period continues until the death of the patient and up to 5 years from 
randomization.  Patients who complete the Treatment Phase with significant residual non-
hematopoietic toxicity will be followed for up to 4 additional weeks until toxicity 
resolves to ≤ grade 1, stabilizes or initiation of new therapy, whichever occurs first.  
Patients with unresolved AEs after 4 weeks will have the events classified as permanent 
sequelae. 
 
Follow-up for CR duration, EFS and Adverse Events (if applicable) are discontinued at 
the time of relapse, start of salvage or non-protocol treatment for leukemia (for persistent 
disease). All patients who have persistent or relapsed disease or who are transferred for 
stem cell transplant will be followed for up to 5 years for relapse and survival. 
  
4.10 Study Modification/Discontinuation 
Any modifications to the study will be documented in a revised protocol with a new 
assigned version.  The revised protocol will have an appendix which will detail the 
revisions to the document. 
 
The Sponsor may stop the trial early for the following reasons: 
• Unacceptable toxicity 
• Discontinuation of drug development 
• Poor enrollment 
• Request by a regulatory authority 
In the case of study discontinuation, all participating institutions will be notified with 
procedures for discontinuing patients from the trial and informing the EC/IRBs (See 
Section 12.5). 
 
4.11 Data and Safety Monitoring Board 
A data and safety monitoring board (DSMB) will periodically monitor the ongoing study 
for safety and efficacy considerations. The DSMB will consist of independent reviewers 
who are not directly involved in the conduct of the study and will advise the Sponsor of 
any trends or safety issues which may impact the study and/or the study patients.  The 
DSMB will operate according to a charter which will be reviewed and ratified before the 
initiation of the study. The DSMB, at a minimum, will: 
• Consist of at least 2 hematologists + 1 cardiologist + 1 statistician  
• Hold at least five meetings: Before the study starts, at 25%, 50%, 75% of accrued 
patients and at end of study to review day 60 deaths and SAEs 
• Conduct a single interim analysis after 60 patients (30 per arm) have been 
evaluated for induction mortality with early stop rules.  Study stops if the 60 day 
death rate in either arm is unacceptable as determined by the DSMB. 
 
4.12 Central Review of Diagnosis and Response: 
Participating centers are required to provide documentation of each patient’s antecedent 
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Every attempt will be made to confirm eligibility at time of randomization. After 
randomization, this documentation will be independently reviewed and the diagnosis 
confirmed.  If there is doubt about the diagnosis of t-AML, MDSAML or CMMoLAML 
during the process of independent review, additional materials will be requested and 
reviewed.  The specific requirements for diagnosis and details of the process for review 
and confirmation of diagnosis will be detailed in a separate operating plan.   
 
In addition, an independent review of hematopathology and peripheral blood reports will 
be done to document response (CR+CRi) to therapy. A charter will be reviewed and 
ratified prior to the initiation of the study. The central reviewer will also be a non-voting 
member of the DSMB, providing the committee with progress reports on the quality of 
diagnostic and response documentation.  
 
5.0 Selection and Withdrawal of Patients 
5.1 Study Population 
5.1.1 Inclusion criteria 
5.1.1.1 Ability to understand and voluntarily sign an informed consent form 
5.1.1.2 Age 60-75 years at the time of diagnosis of AML 
5.1.1.3 Pathological diagnosis of AML according to WHO criteria (with at least 20% 
blasts in the peripheral blood or bone marrow) 
5.1.1.4 Documentation of Antecedent Hematologic Disorder: 
o Therapy-related AML: Documentation of prior cytotoxic therapy or 
radiation therapy for an unrelated disease in a discharge summary or 
pharmacy records or radiation therapy records 
o MDSAML: Bone marrow documentation of MDS prior to diagnosis of 
AML 
o CMMoLAML:  Bone marrow documentation of CMMoL prior to diagnosis 
of AML 
o de novoAML with FISH or cytogenetic changes linked to MDS per WHO 
criteria (see APPENDIX 3: WHO Classification of Secondary Acute 
Myeloid Leukemia18) 
5.1.1.5 Eastern Cooperative Oncology Group (ECOG) performance status 0-2 
5.1.1.6 Able to adhere to the study visit schedule and other protocol requirements 
5.1.1.7 Laboratory values fulfilling the following: 
o Serum creatinine < 2.0 mg/dL 
o Serum total bilirubin < 2.0 mg/dL, patients with Gilbert’s Syndrome 
should contact the medical monitor 
o Serum alanine aminotransferase or aspartate aminotransferase < 3 times 
the ULN. Note:  If elevated liver enzymes are related to disease; contact 
medical monitor to discuss. 
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5.1.1.9 Patients with second malignancies in remission may be eligible if there is 
clinical evidence of disease stability for a period of greater than 6 months off 
cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., 
at screening.  Patients maintained on long-term non-chemotherapy treatment, 
e.g., hormonal therapy, are eligible. 
 
5.1.2 Exclusion Criteria 
5.1.2.1 Patients with history of myeloproliferative neoplasms (MPN) (defined as a 
history of essential thrombocytosis or polycythemia vera, or idiopathic 
myelofibrosis prior to the diagnosis of AML) or combined MDS/MPN are not 
eligible. 
5.1.2.2 Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including 
t(8;21) or inv 16 if known at the time of randomization. 
5.1.2.3 Clinical evidence of active CNS leukemia 
5.1.2.4 Patients with active (uncontrolled, metastatic) second malignancies are 
excluded.  
5.1.2.5 Prior treatment intended for induction therapy of AML; only hydroxyurea is 
permitted for control of blood counts.  For example, a patient with MDS that 
changes HMA dose and schedule after the diagnosis of AML is excluded.  
AML-type therapy, such as cytarabine alone (>1g/m2/day) or cytarabine plus 
an anthracycline as well as prior HSCT are also excluded. 
5.1.2.6 Administration of any therapy for MDS (conventional or investigational) must 
be completed by 2 weeks of the first dose of study drug; in the event of 
rapidly proliferative disease use of hydroxyurea is permitted until 24 hours 
before the start of study treatment. Toxicities associated with prior MDS 
therapy must have recovered to grade 1 or less prior to start of treatment. 
5.1.2.7 Any major surgery or radiation therapy within four weeks  
5.1.2.8 Patients with prior cumulative anthracycline exposure of greater than 368 
mg/m2 daunorubicin (or equivalent), see APPENDIX 8: Anthracyclines 
Equivalents Guidelines 
5.1.2.9 Any serious medical condition, laboratory abnormality or psychiatric illness 
that would prevent obtaining informed consent 
5.1.2.10 Patients with myocardial impairment of any cause (e.g. cardiomyopathy, 
ischemic heart disease, significant valvular dysfunction, hypertensive heart 
disease, and congestive heart failure) resulting in heart failure by New York 
Heart Association Criteria (Class III or IV staging) 
5.1.2.11 Active or uncontrolled infection; patients with an infection receiving 
treatment (antibiotic, antifungal or antiviral treatment) may be entered into the 
study but must be afebrile and hemodynamically stable for ≥72 hrs. 
5.1.2.12 Current evidence of invasive fungal infection (blood or tissue culture); 
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to be eligible; known HIV (new testing not required) or evidence of active 
hepatitis B or C infection (with rising transaminase values) 
5.1.2.13 Hypersensitivity to cytarabine, daunorubicin or liposomal products 
5.1.2.14 History of Wilson’s disease or other copper-metabolism disorder 
5.2 Withdrawal of Patients 
Patients will be discontinued from the Treatment Phase and enter the Follow-up Phase for 
assessment of efficacy endpoints under the following circumstances: 
• Completion of Treatment Phase 
• Persistent disease:  lack of a response to treatment  
• Relapsed disease:  re-appearance of disease following CR or CRi 
• Unacceptable toxicity 
• Patient non-compliance with protocol 
• Administration of non-protocol chemotherapy 
• Intercurrent illness which, in the judgment of the investigator, affects assessment 
of clinical status to a significant degree, and requires discontinuation of protocol 
therapy. 
During any phase of the study, if a patient requests to stop treatment and/or follow-up, 
the patient will be discontinued and no further information will be collected.  The patient 
will be classified as withdrawal of consent.  Any patient that dies on or before Day 7 will 
be replaced.  
6.0 Treatment of Patients 
See APPENDIX 1: Patient Evaluation Flow Sheet
 
6.1 Pre-Treatment Evaluations 
After providing informed consent, eligible patients are registered by providing 
documentation of high-risk (secondary) AML to the sponsor PRIOR to randomization.  
The list of required documents can be found in Section 4.3 on page 25. 
 
The date of the first test or exam will be considered as the date of the screening visit. 
Procedure  Evaluation Timing 
Informed Consent It should be personally signed and dated by 
the patient. The responsible investigator 
must also personally sign and date the 
document. 
A copy of the Informed Consent must be 
given to the patient. 
The patient’s study screening must be 
conspicuously noted in the source 
documentation. 
Informed consent should be 
obtained prior to initiation 
of screening procedures. If 
the period between ICF 
signature date and screening 
visit is ≥30 days the patient 
must sign another ICF. 
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Procedure  Evaluation Timing 
Medical History Complete medical history 
• Resolved conditions 
• Intermittent conditions 
• Concurrent illnesses 
• Previous surgeries 
Within 14 days prior to 
randomization 
Leukemia History • Leukemia, MDS, CMMoL History 
• Prior chemotherapies 
• Prior hypomethylating agents 
Within 14 days prior to 
randomization 




ECOG Performance Status 
Within 3 days prior to 
randomization 




Within 3 days prior to 
randomization 
Hematology Hemoglobin 
White Blood Count 
Platelets 
Differential Count 







Electrolytes (Sodium, Potassium, Chloride) 
Bilirubin 
Alkaline phosphatase 






Within 1 day prior to 
randomization 
Copper levels Serum copper (performed by a central 
laboratory) 














Within 14 days prior to 
randomization 
Diagnostic Imaging Chest X-ray or Chest CT 
Echocardiography or MUGA scan (sent to a 
central laboratory) 
Within 28 days prior to 
randomization 
ECG  Within 14 days prior to 
randomization 
Cytogenetics  Cytogenetics (performed locally) 
 
Within 3 months prior to 
randomization:  patients 
may be randomized and 
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Procedure  Evaluation Timing 
Cytogenetics (performed by a central 
laboratory):  For those centers that have a 
turn-around of 7 or more days, a central 
laboratory will be made available to screen 
de novo patients for eligible karyotypes 
(See APPENDIX 3: WHO Classification of 
Secondary Acute Myeloid Leukemia18.  A 
separate informed consent form is used to 
screen de novo patients for eligible 
karyotypes with a short eligibility checklist.  
See Section 9.4.3. 
cytogenetic test results; 
however, every attempt 
should be made to have the 
results prior to 
randomization 
Molecular Studies Central laboratory evaluation of CEBPA, 
FLT3, and NPM1  
Within 3 months prior to 
randomization:  patients 
may be randomized and 
treated prior to receiving the 
results of molecular tests 
 
6.2 Evaluation during Treatment Phase 
Inductions and consolidations are administered as courses.  A course consists of the 
administration of therapy with scheduled assessments to evaluate the response to 
treatment.  The first induction may end before the completion of all evaluations if a 
second induction is necessary, (see Section 4.6).  Induction is completed when a patient 
has 
• A confirmed CR (see section 8.4) 
• A CRi (see section 8.4) and is to begin consolidation treatment before 
hematologic count recovery 
• Persistent/recurrent disease (PD/relapse) 
• Response evaluation cannot be performed because of the patient’s condition and 
no further study treatment can or will be administered. 
 
Patients with a CR or CRi may receive up to two consolidation treatments.  Evaluations 
on Days 1-7 must be performed on the day indicated; all other evaluations are to be 
performed on the Study Day indicated plus or minus 2 days.  Each course requires the 
following evaluations: 
 
Procedure Evaluation Timing 
Physical Exam Objective review of body systems 
Weight 
BSA 
Days 14 and 42 




Days 14 and 42 
Hematology Hemoglobin 
White Blood Count 
Platelets 
Differential Count 
Days 1, 3, 5, 7, 10±1, 14±2, then 
weekly (±2days) until whichever 
occurs last: 
- Day 42  
- peripheral blood count recovery 
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Days 1, 3, 5, 7, 10±1, 14±2, then 
weekly (±2days) until whichever 
occurs last: 
- Day 42  
- peripheral blood count recovery 
- removed from Treatment Phase 
PK sampling Plasma concentrations for 
cytarabine and daunorubicin and 
metabolites (performed by 
bioanalytical laboratory) 
CPX-351 patients will be sub-
randomized to one of two PK sampling 
schedules: 
Schedule 1:  Day 1: 45 min, 3 hrs, 8 
hrs, prior to dosing on Day 3 (48 hrs 
(+/- 6 hrs)) or  
Schedule 2: Day 1: End of Infusion, 2 
hrs, 6 hrs, prior to dosing on Day 5 (96 
hr (+/- 6 hrs)).  The exact time and date 
of drug administration and of the PK 
samples will be documented in the 
CRF.  Four samples are collected from 
each patient randomized to CPX-351. 
Copper levels Serum Copper (performed by a 
central laboratory) 
After the last induction that the patient 
receives; See Section 9.4.1 for details 
Bone Marrow Evaluation Morphology 
 
Required at Day 14-21 after every 
induction; Required at recovery to 
confirm response (CR/CRi) or 
persistent disease; in case Day 14-21 
bone marrow is non-evaluable or 
assessment of a morphologic leukemia-
free state is equivocal, a repeat 
evaluation may be performed 5-14 days 
later, at the discretion of the treating 
physician, in order to determine 




Cytogenetics (performed locally) 
Molecular Studies (performed by 
a central laboratory) 
Required in patients with a CR or CRi 
with positive baseline findings 
(perform at the time of bone marrow 
assessment for CR or CRi). Optional in 
patient with normal findings at baseline 
Diagnostic Imaging Echocardiography or MUGA scan 
(sent to a central laboratory) 
After the last induction that the patient 
receives; See Section 9.3 for details 
Response Assessment  See Section 8.4.1
Adverse Events/Toxicity CTCAE v.3 assessment Continual assessment starting from the 
first dose until 30 days after completion 
of the Treatment Period. 
Concomitant Medications GCSF 
Anti-infectives 
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6.3 Day 150 Evaluations  
All patients randomized to this protocol must have the following assessments performed 
150 (±10) days from randomization or 45 days after the last treatment, whichever is later. 
These evaluations are required even if patients have discontinued treatment for persistent 




6.4 Early Termination or End of Treatment Phase 
Any patient that completes or discontinues treatment must have the following evaluations 
performed within 30 days after termination and prior to the initiation of any salvage 
therapy, if not performed within the last 30 days: 
 
Procedure Evaluation Timing 
Diagnostic Imaging Echocardiography/MUGA Within 30 days after discontinuation if 
a study has not been performed since 
last treatment or before the initiation of 
any non-protocol treatment 
ECG  Within 30 days after discontinuation 
Adverse Events/Toxicity CTCAE v.3 assessment  Assess Adverse events that were 
ongoing at the time of discontinuation 
and record and report any new serious 
adverse events (up to 30 days after 
discontinuation) 
Response Assessment Best Response 
Reason for End of Treatment 
 
 
6.5 Evaluation during Follow-up Phase 
The following evaluations are completed during the follow-up phase: 
 
 Evaluation Timing 
ECG  Day 150 ±10 days 
Copper levels Serum Copper (performed by a 
central laboratory) 
Day 150 ±10 days 
See Section 9.4.1 for details 
Diagnostic Imaging Echocardiography or MUGA scan 
(sent to a central laboratory) 
Day 150 ±10 days 
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Procedure Evaluation Timing 
Survival status  
 
Once monthly until 1 year from 
randomization, after the first year record 
only the date of death or alive at Year 5 
(Day 1825).  
Patient status report 
Relapse status 
New anti-leukemic therapies 
Once monthly until 1 year from 
randomization, after the first year record 
only the date of relapse and any new 
leukemic therapies. 
Hematology Hemoglobin 
White Blood Count 
Platelets 
Differential Count 
Once monthly until 1 year from 
randomization or the initiation of new 
therapy and/or relapse 
Bone Marrow Evaluation Morphology 
 
For patients in CR or CRi perform at any 
time that there is a suspicion of relapse. 
For patients in CR, perform if peripheral 
blood counts fall below 1000/μL for 
ANC or 100,000/μL for platelets for >1 
month or at any time there is suspicion 
of relapse. For patients in CRi perform if 
counts fall significantly below peak 
recovery levels.  If the peripheral blood 
counts in a patient with a CRi recover to 
CR levels (≥1000/μL for ANC or 
≥100,000/μL for platelets), perform a 
bone marrow evaluation within 14 days 
to confirm CR.  Following the first year 
of follow up, record relapse information, 
including any bone marrow evaluations.  
Not required following relapse. 
Diagnostic Imaging Echocardiography or MUGA If last LVEF was reduced >10% from 
baseline and is less than 50% repeat 
every 3 months until LVEF returns to 
baseline or until 1 year from 
randomization.  Persistent reductions in 
LVEF of >10% and failing below 50% 
lasting >1 year are considered 
permanent sequelae.  
Biochemistry BUN 
Creatinine 









Perform monthly only if 
abnormality(ies) persists at the end of 
the Treatment Phase.  Perform until 
abnormality(ies) returns to baseline, 
until 1 year from randomization, or the 
initiation of new therapy and/or relapse. 
(which ever is earliest) 
Copper levels Serum Copper (performed by a 
central laboratory) 
If elevated copper (>20% above ULN) 
persists at Day 150 perform monthly 
until abnormality returns to baseline or 
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Procedure Evaluation Timing 
Adverse Events/Toxicity CTCAE v.3 assessment  Assess AEs that were ongoing at the 
time of discontinuation. Do NOT record 
any new AEs.  AEs that persist without 
evidence of recovery for >30 days are 
considered permanent sequelae and do 
not require further follow-up. 
 
7.0 Drug Administration 
The responsibility for treatment of patients rests with the individual investigator.  
Protocol treatment must begin within 24 hours of randomization. 
 
First Induction: 
Arm Agent Dose Route Duration Schedule 
A CPX-351 100u/m2/day IV 90 minutes* Days 1, 3 and 5  
Cytarabine 100mg/m2/day IV 7 days Days 1-7 by continuous infusion B Daunorubicin 60mg/m2/day IV Push 15 minutes Days 1, 2 and 3 
 
Second Induction: 
Arm Agent Dose Route Duration Schedule 
A CPX-351 100u/m2/day IV 90 minutes* Days 1 and 3  
Cytarabine 100mg/m2/day IV 7 days Days 1-5 by continuous infusion B Daunorubicin 60mg/m2/day IV Push 15 minutes Days 1and 2 
 
Consolidations (up to two are permitted): 
Arm Agent Dose Route Duration Schedule 
A CPX-351 65u/m2/day IV 90 minutes* Days 1 and 3 
Cytarabine 100mg/m2/day IV 5 days Days 1-5 by continuous infusion B Daunorubicin 60mg/m2/day IV Push 15 minutes Days 1 and 2 
*Approximately 
7.1 Drug Preparation and Administration 
7.1.1 CPX-351 
7.1.1.1 Drug Preparation 
The appropriate number of vials of CPX-351 (cytarabine:daunorubicin) Liposome 
Injection should be removed from the refrigerator prior to reconstitution.  Reconstitute 
with 19 mL of sterile water for injection using a 20 mL syringe. Do not heat CPX-351 
(cytarabine:daunorubicin) Liposome Injection.  After reconstitution, invert vials gently 3-
4 times and let rest for 15 minutes and repeat vial inversion prior to withdrawing drug for 
dilution.  The concentration of the reconstituted dispersion is 5 u/mL.  CPX-351 
(cytarabine:daunorubicin) Liposome Injection should be diluted in approximately 500 
mL of sodium chloride injection or dextrose injection. 
 
The IV bags and infusion sets must be non-DEHP.  Aseptic technique must be strictly 
observed throughout the handling of CPX-351 (cytarabine:daunorubicin) Liposome 
Injection since no bacteriostatic agent or preservative is present.  The infusion of CPX-
351 (cytarabine:daunorubicin) Liposome Injection must be started within 4 hours of 
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discarded according to institutional policies.  Procedures for proper handling and disposal 
of anticancer drugs should be implemented. 
 
7.1.1.2 Drug Administration 
The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be 
performed through a central venous catheter, using an infusion pump to ensure that the 
drug is infused over the specified time period.  Non-DEHP containing administration sets 
should be used.  Do not use an in-line filter.  CPX-351 should never be given by the 
intramuscular or subcutaneous route.  Administer CPX-351 over approximately 90 
minutes via an infusion pump.  Flush the line to ensure administration of the full dose. 
 
The dosage (total units and u/m2), start/stop time of the infusion, total volume infused, 
must be documented in the patient’s chart. 
7.1.2 Cytarabine and Daunorubicin “7+3” 
7.1.2.1 Control Arm Drug Sourcing: 
The drug products that may be used for the control arm will be sourced by the 
investigational site.  Cytarabine and daunorubicin are approved in the US, Canada and 
EU and will be obtained from the appropriate market (US for investigational sites in the 
US, Canadian for sites in Canada, EU country for sites in EU).  If for any reason, drug 
supplies for cytarabine or daunorubicin are or might be unavailable or insufficient to 
complete a treatment cycle, contact the sponsor as soon as possible:  Telephone: +
 or fax:  or email: .  
 
7.1.2.2 Cytarabine 
Cytarabine is not provided as a study drug and must be supplied by the treating 
institution.  Prepare and administer cytarabine according to institutional guidelines and 
the package insert.  Below are general guidelines for preparation and administration. 
 
The drug is available in vials of 100mg, 500mg, 1g and 2g – containing white lyophilized 
substance. The drug must be reconstituted prior to use. 
 
A solution in which a slight haze develops should not be used, it should be discarded and 
another dose of the drug should be prepared. The ready solution should be stored at 
temperatures of 15-30˚C. The solution should not be stored for prolonged periods of time 
and infusion should start as soon as feasible. All infusion solutions must be inspected 
visually for particulate matter and discoloration prior to administration.  The dosage (total 
mg and mg/m2), start/stop time of the infusion, total volume infused, must be documented 
in the patient’s chart. 
 
Cytarabine is administered as a 7 day (for first induction) or 5 day (for second induction 
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Daunorubicin is not provided as a study drug and must be supplied by the treating 
institution.  Prepare and administer daunorubicin according to institutional guideline and 
the package insert.  Below are general guidelines for preparation and administration. 
 
The drug is provided as the HCl salt in vials containing a reddish lyophilized powder 
which should be reconstituted for infusion.  Vials of 20 mg and 50 mg are available.  The 
smaller packaging vials contain the equivalent of 20mg daunorubicin base (21.4 
daunorubicin HCl - lyophilized powder) and 100mg mannitol. Each 50 mg vial contains 
53.5 mg daunorubicin hydrochloride, equivalent to 50 mg daunorubicin base, and 250 mg 
of mannitol.  The contents of the 20 mg vial should be reconstituted with 4 mL of Sterile 
Water for Injection, USP, and agitated gently until the material has completely dissolved. 
The sterile vial contents provide 20 mg of daunorubicin, with 5 mg of daunorubicin per 
mL.  The contents of the 50 mg vial should be reconstituted with 10 mL of Sterile Water 
for Injection, USP, and agitated gently until the material has completely dissolved. The 
sterile vial contents provide 50 mg of daunorubicin, with 5 mg of daunorubicin per mL. 
The reconstituted solution is stable for 24 hours at room temperature and 48 hours if 
refrigerated.  The desired dose is withdrawn into a syringe containing 10 mL to 15 mL of 
0.9% Sodium Chloride Injection, USP.  Daunorubicin should not be administered mixed 
with other drugs or heparin.  Store the unreconstituted powder according to label 
instructions at a controlled room temperature, 15-30°C (59-86°F).  The dosage (total mg 
and mg/m2), start/stop time of the infusion, total volume infused, must all be documented 
in the patient’s chart. 
 
Daunorubicin Hydrochloride for Injection is administered intravenously into the tubing or 
sidearm in a rapidly flowing intravenous infusion. It must never be given by the 
intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is 
extravasation during administration. 
 
7.2 Drug Accountability 
The study pharmacist or designee must maintain records of the delivery of CPX-351 to 
the study site, the inventory at the site, the use by each patient, and the disposition of 
unused product. These records should include dates, quantities, lot numbers, expiration 
dates and patient identifications.  Institutions should maintain records that document 
adequately that the patients were provided the doses specified by the protocol and 
reconcile all investigational product received from the Sponsor.  Records of storage 
conditions (temperature logs) must be kept for the entire period that CPX-351 is 
maintained at the institution. 
 
7.3 Dose Reductions and Delays 
It is the intention of the study to treat every patient at full dose.  Doses may be delayed 
due to toxicities (for example hypersensitivity reactions).  Any doses missed or delayed 
due to toxicity may be administered as soon as the patient has recovered from the 
toxicity.  Investigators may contact the Medical Monitor to request delay or 
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graded using the CTCAE Version 3.0 (See APPENDIX 5: Common Terminology 
Criteria for Adverse Events V3.0 (CTCAE)).  Toxicities for cytarabine and daunorubicin 
are relatively well known, and are outlined in the product information for each of these 
drugs. 
7.4 Concomitant Therapy 
7.4.1 Premedication 
7.4.1.1 CPX-351 
Nausea and vomiting: 




Patients will not be routinely premedicated for hypersensitivity or infusion-related 
reactions initially during the first infusion of the first treatment course.  If the patient 
develops a hypersensitivity reaction then he/she should be pre-medicated at all 
subsequent infusions. 
 
Suggested guidelines for management of hypersensitivity reactions: 
 
Mild symptoms (e.g., mild flushing, rash, pruritus): 
Stop infusion and supervise at bedside with monitoring of vital signs 
Reinitiate infusion slowly (halving the rate of infusion) +/- premedication 
 
Moderate symptoms (e.g. moderate rash, flushing, mild dyspnea, chest discomfort): 
Stop infusion and give IV diphenhydramine, 20-25 mg (or equivalent) and IV 
dexamethasone 10 mg. 
Do not reinitiate infusion.  Premedicate on re-treatment.  Retreat at same dose and rate. 
 
Severe/life-threatening symptoms (e.g. hypotension requiring vasopressor therapy, 
angioedema, respiratory distress requiring bronchodilation therapy, generalized 
urticaria): 
Stop infusion.  Administer IV diphenhydramine and dexamethasone as indicated above.  
Add epinephrine (adrenaline) or bronchodilators if indicated.  Do not reinitiate infusion.  
Do not retreat. Report as a serious adverse event. 
 
If hypersensitivity or infusion-related reactions become a clinically relevant toxicity, then 
premedication for hypersensitivity reactions will be instituted with drugs, doses and 
schedule according to each investigator’s preference.  Additionally, a decision may be 
made to prolong the infusion time to two hours or more. 
 
7.4.1.2 Daunorubicin and Cytarabine 
Premedication for daunorubicin and cytarabine are provided according to institutional 
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7.4.2 Permitted therapy 
Patients may receive ongoing supportive and palliative care (e.g. pain control) as 
clinically indicated throughout the study. 
 
Infection Prophylaxis:  Prophylactic use of anti-infectives is highly recommended during 
the period of profound neutropenia until ANC returns to 500/μL or greater. The choice of 
anti-infectives will be according to institutional protocol. Use of anti-infective agents as 
prophylaxis and treatment must be documented on the case report forms. 
 
Growth Factor support: The use of growth factors will be according to institutional 
protocol and according to ASCO criteria.16 Use of growth factors must be documented on 
the case report forms. 
 
Transfusion support:  The use of transfusion support (RBCs and platelets) will be 
according to institutional protocol.  Use of transfusion support must be documented on 
the case report forms. 
 
7.4.3 Therapy that is not permitted 
Other anti-cancer treatment and other investigational therapy(ies) are not permitted 
during the Treatment Phase.  In the event of persistent disease or relapse the patient may 
receive other anti-leukemic therapies and is followed for survival. 
 
7.5 Duration of Protocol Treatment 
Patients may continue on study provided they have not met the criteria for 
discontinuation of therapy (See Section 5.2).  The table below summarizes the expected 
duration of the Treatment Phase.  Patients may receive up to two induction courses 
followed by up to two consolidation courses.  After the Treatment Phase, patients are 
followed for up to 5 years from the time of randomization.  
 







1 ~ 42-56 days 5 years 
2 ~ 84-112 days 5 years 
3 ~ 126-168 days 5 years 
4 ~ 168-224 days 5 years 
 
8.0 Assessment of Efficacy 
8.1 Evaluable for Efficacy 
All analyses will be based on the intent-to-treat principle; all randomized patients are 
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8.2 Overall Survival  
All randomized patients are assessed for overall survival.  Overall survival is measured 
from the date of randomization to death from any cause, patients not known to have died 
at last follow-up are censored on the date they were last known to be alive. Patients will 
be followed for up to 5 years.  Overall survival will be analyzed on an intent-to-treat 
basis with all randomized patients analyzed.  A sensitivity analysis will be performed in 
which patient receiving hematopoietic bone marrow transplant are censored for survival 
at the start of conditioning therapy, to eliminate transplant as a confounding factor in the 
analysis of overall survival.  For more detail, see Section 11.5.5. 
8.3 Event-free Survival 
All randomized patients are assessed for Event-free survival. Event-free survival is 
defined as the time from study randomization to the date of induction treatment failure 
(persistent disease), relapse from CR or CRi or death from any cause, whichever comes 
first.  Patients alive and not known to have any of these events are censored on the date 
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8.4 Response Assessment Criteria 




Bone marrow blasts <5%; absence of blasts with Auer 
rods; absence of extramedullary disease; absolute 
neutrophil count >1.0 x 109/L (1000/μL); platelet count 
>100 x 109/L (100,000/μL); independence from red cell 
transfusions 
CR with incomplete 
recovery (CRi)b
All CR criteria except for residual neutropenia (<1.0 x 
109/L [1000/μL]) or thrombocytopenia (<100 x 109/L 
[100,000/μL]) 
Best Response See Section 8.4.2
Treatment failure  
Persistent Disease (PD) 
 
Failure to achieve CR or CRi; only includes patients 
surviving ≥7 days following completion of initial 
treatment, with evidence of persistent leukemia  (blasts in 
peripheral blood, extramedullary leukemia, or persistence 
in the bone marrow) 
Death in aplasia Deaths occurring ≥7 days following completion of initial 
treatment while cytopenic; with an aplastic or hypoplastic 
bone marrow obtained within 7 days of death, without 
evidence of persistent leukemia 
Death from 
indeterminate cause 
Deaths occurring before completion of therapy, or <7 days 
following its completion; or deaths occurring ≥7 days 
following completion of initial therapy with no blasts in 
the blood, but no bone marrow examination available at 
recovery 
Relapsec Bone marrow blasts ≥5%; or reappearance of blasts in the 
blood after achievement of a CR or CRi; or development 
of extramedullary disease 
aBone marrow assessment REQUIRED to confirm CR. All criteria need to be fulfilled; marrow evaluation 
should be based on a count of 200 nucleated cells in an aspirate with spicules; if ambiguous, consider 
repeat exam after 5 to 7 days; flow cytometric evaluation may help to distinguish between persistent 
leukemia and regenerating normal marrow; a marrow biopsy should be performed in cases of dry tap, or if 
no spicules are obtained; no minimum duration of response required. 
b Bone marrow assessment REQUIRED to confirm CRi. Some patients may not achieve complete 
hematologic recovery prior to initiation of consolidation.  CRi cannot be declared earlier than Day 35 to 
allow adequate time for documentation of peripheral blood recovery.  Consolidation may begin no earlier 
than 35 days after the last induction course. 
cIn cases with low blast percentages (5-10%), a repeat marrow should be performed to confirm relapse. 
Appearance of new dysplastic changes should be closely monitored for emerging relapse. In a patient who 
has been recently treated, dysplasia or a transient increase in blasts may reflect a chemotherapy effect and 
recovery of hematopoiesis. 
 
















IND 72,939 PROTOCOL CLTR0310-301 
CPX-351 (cytarabine:daunorubicin) Liposome Injection May 22, 2012, Version 1.0 
 
CONFIDENTIAL Page 44 of 69  
CELATOR PHARMACEUTICALS, INC. 
8.4.1 Timing of response assessment 
In general, the patient’s response to induction therapy is made on the first day when all 
criteria for CR or treatment failure are met.  The bone marrow assessment and the 
peripheral counts are not required to be performed on the same day but recovery of 
counts (including absence of peripheral blasts) must be performed within 14 days of the 
bone marrow assessment.  The timing of other outcomes is recorded as follows: 
1. After one or two induction course(s), PD is declared on the day of the bone 
marrow showing persistent AML. 
2. CRi is declared on or after Day 35 following the last induction course when the 
patient’s bone marrow (performed between day 35-56) demonstrates absence of 
leukemia and the peripheral blood counts have partially recovered but appear 
stable (performed at least twice between day 35-56). 
3. For patients with sufficient blood count recovery (ANC ≥500/μL and platelets 
≥50,000/μL) that consolidation therapy is planned, CRi is declared on the day 
consolidation therapy is initiated but the peripheral counts have not met the full 
CR criteria.  Consolidation must begin after day 35. 
 
8.4.2 Best Response 
Patients who complete the induction(s) with a response of CRi may be upgraded to a CR 
during or after consolidation if the patient’s peripheral blood counts meet the criteria for 
CR after declaration of a CRi.  To upgrade a response to CR both peripheral blood and 
bone marrow assessment are not required on the same day but must be obtained within a 
14 day period of each other and all criteria for CR must be met (within a 14 day period 
must have full recovery AND be leukemia-free). 
8.5 Remission Duration 
Only patients achieving CR or CRi are assessed for remission duration. Remission 
duration is measured from the date of achievement of a remission (CR/CRi) until the date 
of relapse or death from any cause; patients not known to have relapsed or died at last 
follow-up are censored on the date they were last examined.  For patients whose best 
response is upgraded from CRi to CR, remission duration will be calculated from date of 
CRi to date of relapse or death. 
8.6 Morphologic Leukemia-free State 
All randomized patients that have at least one evaluable post-randomization bone marrow 
assessment performed on or after Day 14 after the last induction are assessed for 
morphologic leukemia-free state.  Morphologic leukemia-free state is defined as bone 
marrow blasts <5% AND absence of Auer rods and/or extramedullary disease.1 
8.7 Stem Cell Transplant 
The number and percentage of patients transferred for stem cell transplant will be 
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9.0 Assessment of Safety  
9.1 Evaluable for Safety 
All patients who have received at least one dose will be considered evaluable for safety. 
9.2 Adverse Events 
9.2.1 Definition of an Adverse Event 
An adverse event is any untoward medical occurrence in a patient or clinical 
investigation subject administered with a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment. An adverse event can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding, for example), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product. This 
includes worsening of a pre-existing condition or increase in frequency of a pre-existing 
condition. An adverse event is considered serious if it meets any of the serious criteria 
listed in Section 9.2.2.  To ensure no confusion or misunderstanding of the difference 
between the terms “serious” and “severe”, which are not synonymous, the following 
clarification is provided: 
 
The term “severe” is often used to describe the intensity (severity) of a specific event (as 
in mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as 
“serious”, which is based on patient/event outcome or action criteria usually associated 
with events that pose a threat to a patient’s life or functioning. Seriousness (not severity) 
serves as a guide for defining regulatory reporting obligations. 
 
Adverse events are to be recorded in the case report form from the start of the infusion on 
Day 1 to the last day of the treatment period, with the exception of serious adverse 
events. (See Section 9.2.2) 
 
Adverse drug reactions (ADRs) are all noxious and unintended responses to a medicinal 
product related to any dose that a causal relationship between the medicinal product and 
an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled 
out. An unexpected ADR is any adverse reaction not identified in nature or intensity in 
the current Investigator’s Brochure. 
9.2.2 Definition of a Serious Adverse Event 
A serious adverse event (SAE) is any adverse event that at any dose: 
 
Results in death (grade 5) 
Is life-threatening 
Requires inpatient hospitalization or prolongation of existing hospitalization 
Results in persistent or significant disability or incapacity 
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These events are to be reported as serious from the start of the infusion on Day 1 to 30 
days after completion of the treatment period.  Medical and scientific judgment should be 
exercised in deciding whether expedited reporting is appropriate in other situations such 
as important medical events that may not be immediately life-threatening or result in 
death or hospitalization but may jeopardize the patient or may require intervention to 
prevent one of the events listed above. 
 
Exceptions to the definition of SAE are uncomplicated febrile neutropenia and grade 1-3 
bleeding events (with or without platelet transfusions).  These events, as they are 
common and expected in this patient population will NOT be reported as SAEs, but as 
AEs only. Hospitalizations for routine procedures, investigations and chemotherapy 
administration are NOT considered SAEs in this protocol. 
 
9.2.3 Serious Adverse Event Reporting Instructions 
The investigator must complete the Serious Adverse Event Report Form in English, 
assess the relationship to study treatment and send the completed form by fax within 24 
hours to the Sponsor or its designee.  The original and the duplicate copies of the Serious 
Adverse Event Form, and the fax confirmation sheet must be kept with the case report 
forms at the study site. 
 
Follow-up information is sent to the Sponsor or its designee via the original Serious 
Adverse Event Form, re-stating the date of the original report.  Either a new Serious 
Adverse Event Form is sent (stating that this is a follow-up), or the original one resent 
(with the new information highlighted and a new date provided).  The follow-up should 
describe whether the event has resolved or continues, if and how it was treated, whether 
the patient continued or discontinued study participation.  The form and fax confirmation 
sheet must be retained. 
 
The telephone and fax numbers of the local Clinical Research contact person and the 
contact person in the local department of Clinical Safety, specific to the site, must be 
listed in the investigator folder provided for each individual site and provided to the 
Sponsor or its designee at the start of the trial.  Questions referring to a specific serious 
adverse event occurring in a study patient should be directed to the local Clinical 
Research contact person specified in the investigator folder provided for the site. 
 
9.2.4 Reporting Serious Adverse Events to Regulatory Agencies and Review Boards 
The need for an expedited report to regulatory authorities will be determined by the 
Sponsor’s Medical Monitor.  All AEs that are serious, unexpected and associated with the 
use of CPX-351 will be reported to the applicable regulatory authority (FDA in the US 
and to Health Canada in Canada).  The Sponsor will notify investigators of all such SAEs 
and these reports must be submitted by the investigators to the IRB/EC.  In Europe, these 
SAEs will be submitted to the national competent authorities, EudraVigilance and to ECs 
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9.3 Cardiac Toxicity Monitoring 
As anthracyclines are known to have an adverse effect on cardiac function, each patient’s 
cardiac function will be monitored through the Treatment and Follow-up Phases. Any left 
ventricular ejection fraction below 50% will be recorded as an adverse event. Any 
decrease in LVEF >10% resulting in a nadir LVEF <50% will be reported as an SAE. All 
randomized patients must have an ECHO or MUGA at: 
 
1) Pre-Treatment 
2) after the LAST induction that the patient receives 
a. Responding patients after one or two inductions are assessed 30- 45 days 
after the start of the last induction or before the start of consolidation, 
whichever is later 
b. Non-responding patients will be assessed prior to the start of salvage 
therapy or 30- 45 days after the start of the last induction if salvage 
treatment is not given. 
3) Day 150 or 45 days from last treatment whichever is later 
a. ALL patients must receive an ECHO or MUGA 150 days (±10 days) from 
date of randomization. These evaluations are required even if patients 
have discontinued treatment for persistent or relapsed disease and have 
started salvage therapy or were transferred for HSCT. 
4) Follow-up Period 
a. If the left ventricular ejection fraction is reduced >10% to below 50% 
from the baseline assessment at the last Treatment Phase measurement, 
left ventricular ejection fraction will continue to be monitored every 3 
months until a return to baseline or 1 year, whichever comes first.  These 
evaluations are required even if patients have discontinued treatment for 
persistent or relapsed disease and have started salvage therapy or were 
transferred for HSCT. 
 
All cardiac assessments with ECHO/MUGA scans must be read locally for patient care. 
Assessments will also be sent to a central cardiac vendor who will digitize the scans for 
review at a later date. Details will be provided in the cardiac vendor’s manual.  
 
9.4 Laboratory Data 
Laboratory data obtained according to the schedule of assessments will be recorded on 
the CRF or other data collection instrument. Only laboratory data requested by the 
protocol need be recorded unless specific findings result in a clinical event such as an 
adverse event or documentation of peripheral blood count recovery.  These results will be 
collected. 
9.4.1 Copper Assessment 
Patients will have serum copper assessed routinely until levels return to baseline and the 
percentage of patients with persistent (>1 year) copper elevations will be reported.  Also, 
patients with persistently elevated serum copper will be evaluated for clinical 
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tests).  Serum copper elevations are laboratory values and are not reported as adverse 
events unless associated clinical signs and symptoms of copper toxicity. All randomized 
patients must have a serum copper assessment at: 
 
5) Pre-Treatment 
6) after the LAST induction that the patient receives 
a. Responding patients after one or two inductions are assessed 30- 45 days 
after the start of the last induction or before the start of consolidation, 
whichever is later 
b. Non-responding patients will be assessed prior to the start of salvage 
therapy or 30- 45 days after the start of the last induction if salvage 
treatment is not given. 
7) Day 150 or 45 days from last treatment whichever is later 
a. ALL patients must have a serum copper assessment 150 days (±10 days) 
from date of randomization. This is required even if patients have 
discontinued treatment for persistent or relapsed disease and have started 
salvage therapy or were transferred for HSCT. 
8) Follow-up Period 
a. If elevated copper (20% above ULN) persists at Day 150, perform 
monthly until abnormality returns to baseline or 1 year, whichever comes 
first.  These evaluations are required even if patients have discontinued 
treatment for persistent or relapsed disease and have started salvage 
therapy or were transferred for HSCT. 
 
Copper data will be obtained via a central laboratory.  Investigators will be provided kits 
for the collection of specimens and for sending the samples to the laboratory.  Data 
generated by the laboratory will be incorporated into the case report form database prior 
to the primary endpoint analysis.  Specifics about the specimen collection and processing 
and communication of results will be provided in a separate laboratory manual. 
9.4.2 Molecular Mutations 
Molecular mutation data for CEBPA, FLT3, and NPM1 will be obtained via a central 
laboratory.  Investigators will be provided kits for the collection of specimens and for 
sending the samples to the laboratory.  Data generated by the laboratory will be 
incorporated into the case report form database prior to the primary endpoint analysis.  
Specifics about the specimen collection, and processing and communication of results 
will be provided in a separate laboratory manual. 
9.4.3 Cytogenetic Assessments 
Patients with apparent de novo disease may qualify for the study if they have 
myelodysplastic syndrome-related cytogenetic abnormalities (See APPENDIX 3: WHO 
Classification of Secondary Acute Myeloid Leukemia18 for a list of those abnormalities).  
Cytogenetic results must be available prior to randomization for these patients.  If the 
institution does not perform cytogenetics or does not perform the test rapidly enough to 
initiate timely treatment, the sponsor has made a central laboratory available.  For the 
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form specific to this assessment and must meet some basic inclusion criteria (e.g. age of 
patient).    Results will be rapidly (within 24 hours) reported to the institution and will be 
incorporated into the case report form database prior to the primary endpoint analysis.  
Specifics about the specimen collection, and processing and communication of results 
will be provided in a separate laboratory manual. If a patient has clear documentation of 
MDSAML, t-AML or CMMoLAML (see Table 3: Documents Required for Registering a 
Patient), it is desirable, but not necessary to have the cytogenetics at randomization. 
 
10.0 Other Evaluations 
10.1 Pharmacokinetic Evaluations 
Plasma concentration data collected from PK assessment from CPX-351 treated patients 
will be subjected to non-linear mixed-effect modeling (using the NONMEM program) 
analysis to obtain population PK parameter estimates.  A population PK modeling 
approach will be used to describe plasma concentrations of cytarabine and daunorubicin 
following CPX-351 administration in the targeted patient population. Pharmacokinetic 
parameters such as clearance (CL) and volume (V) for cytarabine and daunorubicin will 
be defined for patients receiving CPX-351. In the analysis, a number of covariates, 
including demographic variables (e.g., age, gender, body weight, and race), clinical 
laboratory markers (e.g., AST, ALT, Creatinine Clearance), and concomitant medications 
will be evaluated to determine if they contribute to differences in the PK estimates among 
individuals.  A separate PK analysis plan will be prepared prior to data analysis. 
 
10.2 Medical Resource Use 
Medical resource use (MRU) data will be collected for all study participants and analyzed 
by health outcomes (overall survival and response (CR+CRi) for CPX-351 vs. control 
arms. The MRU data collected in the trial will be used to identify costs associated with 
planned induction and consolidation treatment and for unplanned medical interventions 
necessary for patient support. Specific MRU data collected will include but may not be 
limited to: 
• hospitalization nights (general ward and intensive care); 
• blood product support (PRBC, Platelets, other);  
• non-chemotherapy drugs (anti-infectives, growth factors, etc.); and  
• AML chemotherapy (induction vs. consolidation). 
 
11.0 Statistical Considerations 
11.1 Study Overview 
This is a randomized phase III study with equal allocation to each of the two treatments: 
100 u/m2 of CPX-351 (arm A) and standard of care (7+3, arm B). This study is designed 
to assess the efficacy and confirm the safety of 100 u/m2 of CPX-351 compared to the 
standard of care (7+3).  A total of 240 patients will be accrued and randomized to obtain 
220 evaluable patients.  This study will use a dynamic allocation procedure to allocate an 
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the marginal distribution of the stratification factors between these treatment regimens 
(see Section 4.1 for stratification factors).  
 
11.2 Primary and Secondary Endpoints 
11.2.1 Primary Endpoint 
The primary objective of this study is to compare overall survival (OS), as defined in 
Section 8.2. All patients who have signed a consent form and have been randomized will 
be evaluable for overall survival.  
11.2.2 Secondary Endpoints 
Secondary efficacy endpoints include overall post induction response (CR+CRi) rate, 
best response (CR+CRi) rate (after completion of the treatment phase), remission 
duration (relapse-free survival) and event-free survival (EFS) as defined in Section 8.   
 
Additional endpoints also include the rate of morphologic leukemia-free state, the rate of 
transfer for stem cell transplant and the following safety assessments:  Deaths, SAEs, 
AEs, laboratory tests, vital signs, ECG, and echocardiography. In addition early (by Day 
30 and 60) deaths will be monitored. 
 
11.3 Sample Size and Power Justification for Primary Endpoint 
The study will accrue 220 evaluable patients (110 per arm). An additional 20 patients (10 
per arm) will be accrued to account for ineligible patients and patients withdrawing 
consent.  All sample size and power justifications are based on evaluable patients only 
and will be referred to as “patients” throughout the remainder of the statistical section. 
Assuming a uniform recruitment of 135 evaluable patients per year, 1.65 years will be 
required to complete enrollment of 220 patients. Furthermore, patients will be followed 
until the last patient enrolled has been followed for ≥1.2 years.  Assuming exponential 
survival, and a median OS of 6 months in the control arm (Arm B), 190 deaths are 
expected to occur after opening of the study, resulting in a study with 94% power and a 
one-sided significance level alpha of 0.025 to detect a hazard ratio of 0.6 between the two 
treatment arms.  Total time for study completion is approximately 2.85 years. 
 
A hazard ratio of 0.41 was observed in the 204 study for sAML patients. To approximate 
the hazard ratio to be expected in the Phase III study, we assumed one half the efficacy 
observed in Phase II which would require a sample size sufficient to detect a hazard ratio 
of approximately 0.60. This study is designed to have 94% rather than 90% power for the 
primary endpoint to assure that the sensitivity analysis which accounts for potential early 
drop-outs due to transplant is adequately powered to 90% for the same hazard ratio of 0.6 
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11.4 Analysis of Primary Endpoint 
Efficacy analysis will be performed on an intent to treat basis. A stratified log-rank test 
will be used to compare the experimental arm (Arm A) to the control arm (Arm B). The 
analysis for the primary endpoint will be performed after 190 deaths (86%) have 
occurred. Assuming exponential survival, uniform recruitment of 135 total eligible 
patients per year, an accrual period of 1.65 years, an additional follow-up period of 1.2 
years and a median overall survival of 6 months, 190 events are expected to occur within 
2.85 years after the opening of the study.  The number of events is based on the 
alternative hypothesis.  In addition, the distribution of OS in each arm will be estimated 
using the method of Kaplan-Meier by treatment group. The hazard ratio and OS rates at 
different time points, along with corresponding confidence intervals will be reported. 
Exploratory multivariate analyses will be performed to assess the treatment effect 
adjusting for key prognostic factors using the Cox proportional hazard regression model. 
This primary efficacy analysis will be performed on the intent-to-treat population. 
 
A detailed statistical analysis plan specifying all planned analyses to be performed will be 
developed for this study before the analyses are conducted. 
 
11.5 Analysis of Secondary Endpoints 
Secondary efficacy endpoints include response (CR+CRi) rate, best response (CR+CRi) 
rate, remission duration (relapse-free survival), and event-free survival (EFS) as defined 
in Section 8.0.   
 
In addition, we will perform a sensitivity analysis to account for patients transferred to 
HSCT (See Section 11.5.5). 
 
All efficacy analyses will be performed on an intent-to-treat basis using the ITT analysis 
population.  
 
11.5.1 Time dependent endpoints  
Time dependent endpoints, such as remission duration and event-free survival (EFS), will 
be evaluated using a stratified log-rank test to compare the experimental arm to the 
control arm. In addition, the method of Kaplan-Meier will be used to estimate and display 
the distribution of these endpoints over time.  Exploratory multivariate analyses will be 
performed to assess the treatment effect adjusting for key prognostic factors using the 
Cox proportional hazard regression model. Specific subgroup analyses will be performed 
to assess whether the treatment effect differs according to the stratification factors.  
11.5.2 Binary Endpoints 
The response (CR+CRi) rate and best response (CR+CRi) rate will be calculated based 
on the responses achieved as defined in section 8.4. The number of patients who achieve 
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Likewise, the rate of achieving a morphologic leukemia-free state will be calculated as 
the number of patients who develop this state, as defined in section 8.6, divided by all 
randomized patients who have at least one evaluable post-randomization bone marrow 
assessment performed on Day14-21 after the last induction. 
 
The rate of stem cell transplant will be calculated by the number of patients starting 
conditioning treatment for stem cell transplant divided by the number of patients who 
have received at least one induction course. 
 
The difference in response rate, morphologic leukemia-free rate and rate of transfer for 
stem cell transplant between the two treatment arms will be calculated using the Mantel-
Haenszel test. These comparisons will be stratified by the stratification factors specified 
in Section 4.1.  In addition, multivariate logistic regression analysis will be performed to 
assess the treatment effect while adjusting for key prognostic factors.  
11.5.3 Analysis Populations 
All efficacy analyses will be performed on an intent to treat basis using the Intent-to- 
treat population as defined in section 11.7. The analysis for transfer to stem cell 
transplant will be performed on the per protocol population as defined in section 11.7. 
Finally, the analysis on morphologic leukemia-free state will be performed on the 
population that achieves a morphologic leukemia-free state as defined in section 11.7.4. 
In addition a sensitivity analysis will be performed on all efficacy endpoints using the per 
protocol population.  Further, the MDS subpopulation, consisting of those with MDS by 
history and patients with MDS by karyotype only; will be analyzed for OS, EFS, 
CR+CRi, best response, response duration and 60-day mortality. 
11.5.4 Power Considerations for the Secondary Efficacy Endpoints 
In the 204 study the observed hazard ratio for event-free survival of the 7+3 arm versus 
the CPX-351 arm was 1.79 (0.56) in the patient population with secondary AML. The 
observed median event-free survival in the control arm was 42 days. This trial design 
with 220 patients total accrued over a period of 1.65 years with a 1.2 year follow-up 
yields 99% power and a one-sided significance level alpha of 0.025 to detect a hazard 
ratio of 1.79 (0.56) between arms. The same trial design yields 94% power (with a one-
sided alpha of 0.025) to detect a hazard ratio of 1.6. These calculations are based on the 
assumption that the events are exponentially distributed. 
 
In the 204 study the observed response rate (CR+CRi) in secondary AML patients was 
approximately 56% in the CPX-351 arm and 32% in the 7+3 arm. This trial design with a 
total of 220 patients yields 94% power and a one-sided significance level alpha of 0.025 
to detect an absolute improvement of 24% in the CPX-351 arm. These calculations are 
based on the assumption that the responses are binomially distributed and that the 
response rate in the control arm (7+3) is 32%. 
11.5.5 Sensitivity Analysis and Power considerations for Sensitivity Analysis 
In the 204 study approximately 19% of patients had HSCT. A sensitivity analysis will be 
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of transplant. This analysis will account for early drop-out due to transplant and will be 
performed on the ITT population. To minimize bias due to transplant, stratification by 
risk which includes age (see Section 4.1) will be used.  
 
We assume the same design considerations as for the sample size calculations for the 
primary endpoint: 220 patients accrued in 1.65 years, followed for 1.2 years, median OS 
in control group 6 months. Using these design considerations and assuming a constant 
drop-out rate in the first year after enrollment due to transplant with a cumulative drop-
out of 20% in each arm, which corresponds to a hazard rate of the competing transplant 
risk of 0.223, yields a study with 90% power (and a one-sided alpha of 0.025) to detect a 
hazard ratio of 0.60.17  We also examined the extreme cases of maximum imbalance 
between arms, when all drop-outs due to transplant occur in just one treatment arm. 
Using the same assumptions as outlined above, but assuming a constant drop-out rate in 
the first year with a cumulative drop out of 40% due to transplant in the CPX-351 arm 
and no drop-out in the 7+3 arm still yields a study with 90% power (and a one-sided 
alpha of 0.025) to detect a hazard ratio of 0.60. Likewise, assuming a constant drop-out 
rate in the first year with a cumulative drop out of 40% due to transplant in the 7+3 arm 
and no drop-out in the CPX-351 arm still yields a study with 90% power (and a one-sided 
alpha of 0.025) to detect a hazard ratio of 0.60. 
 
11.6 Safety Analysis 
Safety data will be analyzed and reported for all patients in the safety population as 
defined in section 11.7. Safety data will be summarized and will include hematology, 
coagulation, chemistries, urinalysis, vital signs, ECG, echocardiography and adverse 
events (AEs).  AEs will be coded using the MedDRA coding dictionary.  Laboratory 
values will be summarized both by actual result and by toxicity grade.  The maximum 
grade for each type of toxicity will be recorded and reported for each patient, and 
frequency tables will be reviewed to determine toxicity patterns. 
 
The laboratory data, vital signs, ECG, and echocardiography will be summarized using 
descriptive statistics (n, mean, standard deviation, median, min and max) at each 
scheduled time point. The number and proportion of patients with reported AEs will be 
tabulated by treatment group. 
 
Early death rates (by Day 30 and 60) will be evaluated separately for each arm by the 
number of deaths occurring in those time intervals divided by the total number of patients 
in the respective arm. 
 
All patients will have serum copper levels assessed at baseline prior to the first dose, after 
the last induction and at Day 150.  Patients with elevated serum copper levels (>20% 
above upper limit of normal) at Day 150 will have monthly serum copper determinations 
until 1 year from randomization or documentation of return of serum copper to normal 
levels. The proportion of patients with elevated serum copper levels after the end of 
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between arms will be made using the Mantel-Haenszel test. These comparisons will be 
stratified by the stratification factors specified in Section 4.1. 
 
A Data and Safety Monitoring Board will oversee the conduct of the study. The Board 
consists of at least two hematologists, one cardiologist, and one statistician.  The 
committee meets at specified intervals and reviews safety data including day 30 and 60 
deaths and SAEs. This Board will be responsible for decisions regarding possible 
termination and/or early reporting of the study. 
 
11.7 Analysis Populations 
11.7.1 Intent-to-treat Population 
The intent-to-treat population is all patients who have been randomized to the trial. 
Patients are assigned to treatment arms based on what they were “randomized” to receive. 
This is the primary efficacy population.  
11.7.2 Safety Population: 
All patients who receive at least one dose of study medication (CPX-351, cytarabine or 
daunorubicin) and have at least one post-baseline safety follow-up. Safety will be 
analyzed using the safety population. Patients are assigned to treatment arm based on 
what they receive.  
11.7.3 Per Protocol Population: 
These patients are a subset of the intent-to-treat population. The per-protocol population 
includes all patients who have met inclusion/exclusion criteria and have received at least 
one dose. The analysis of transfer to stem-cell transplant will be performed on this study 
population.  
11.7.4 Morphologic Leukemia-free State Population 
These patients are a subset of the per-protocol population. The morphologic leukemia-
free state (MLS) population includes all randomized patients who have met 
inclusion/exclusion criteria, have received at least one dose and have at least one 
evaluable post-randomization bone marrow assessment performed on or after Day 14 
after the last induction. 
 
11.7.5 Summary of Analysis Populations 








>3 AE Labs 
ITT X X X X      
Per-protocol X X X X      
MLS   X X X     
Safety      X X X X 
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11.8 Timing of Analyses 
An analysis of induction response (CR+CRi) and 60-day death rate will be performed 
approximately 90-120 days after the start of treatment of the last randomized patient, 
which is after all patients have been accrued, treated and recovered from induction 
treatment.  This response analysis will be reviewed by the DSMB along with the final 
study data for 60-day mortality.  The purpose of this analysis is to allow decisions to be 
made for initializing other clinical trials of CPX-351.  The sponsor believes that use of 
response information will not bias the conduct of the study because all patients will have 
been randomized, treated and followed long enough to recover from hematopoietic effect 
of treatment and because the remaining data to be collected on each patients consists only 
of relapse and survival which are simple and objective.  These analyses will not affect the 
conduct of the trial or the alpha of the primary endpoint.  All other analyses including 
those for overall survival, EFS, best response (CR+CRi) and remission duration will be 
performed after the endpoint for the primary analysis has occurred. 
 
12.0 Administrative, Regulatory and Ethical Issues 
12.1 Direct Access to Source Documents 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents.  Examples of these original documents 
and data records include but are not limited to: hospital records, clinical and office charts, 
laboratory notes, memoranda, patients’ diaries or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions 
certified after verification as being accurate and complete, microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, patient files, and records kept at the 
pharmacy, at the laboratories, and at medico-technical departments involved in the 
clinical trial. 
 
Case report forms, all copies of test results, and study-related regulatory documents [e.g., 
Informed Consents, Institutional Review Board (IRB)/Ethics Committee (EC) 
approvals/correspondence, etc.] must be available at all times for regulatory agency 
inspection and review by the sponsor or its designee. During the periodic site monitoring 
visits, the source documents will be verified against data entered onto the CRF in order to 
assure that all data is accurately and completely reflected on the patient's CRF. 
 
12.2 Study Monitoring and Quality Inspections/Audits 
This study will be monitored by the sponsor or its designee according to GCP/ICH 
guidelines and EU legislation.  A site visit will be held prior to initiation of patient 
enrollment. The protocol, CRFs, study drug supplies, and relevant procedures will be 
explained in detail at the site visit. Subsequent to patient enrollment, a study site monitor 
from the sponsor or its designee will review the CRFs and source documents to ensure 
that the study is conducted according to the protocol and GCP/ICH guidelines and EU 
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To ensure compliance with GCP/ICH guidelines and EU legislation and all applicable 
regulatory requirements, the sponsor or its designee may conduct a quality assurance 
audit.  Regulatory agencies may also conduct a regulatory inspection of this study.  Such 
audits or inspections can occur at any time during or after completion of the study.  If 
audits or inspections occur, the Investigator and the Institution agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and 
the time of his/her staff to the auditor/inspector to discuss findings and any relevant 
issues. The investigator must promptly notify the Sponsor of any audits scheduled by any 
regulatory authorities, and promptly forward copies of audit reports. 
 
12.3 Ethics 
This study will be conducted in accordance with local regulations, EU legislation, GCP, 
ICH guidelines and the Declaration of Helsinki. The Investigator at each site will be 
responsible for the overall conduct of the clinical trial for the site and will be responsible 
for ensuring the trial is conducted according to the protocol and all regulatory 
requirements and IRB/EC regulations. 
 
12.4 Adherence to the Protocol 
Except for a change that is intended to eliminate an immediate hazard to patients, the 
approved protocol will be conducted as described.  If a change in the conduct is made to 
eliminate an immediate hazard, the Sponsor and the IRB/EC are notified immediately. 
 
Deviations from the protocol will be considered in two categories, Protocol Violations 
and Protocol Deviations.  Protocol Violations are those patients who are not eligible 
according to the inclusion/exclusion criteria in effect at the time of randomization.  
Protocol Deviations are all other non-compliance with the protocol, such as missing or 
skipped procedures or evaluations, evaluations performed outside given window, 
incorrect administration of investigational product, etc.. 
 
12.5 Protocol Revisions 
12.5.1 North America 
All revisions must be discussed with, and be prepared by, the Sponsor.  If the revision is 
an Administrative Letter, the investigator should submit it to the IRB/EC for their 
information.  If the revision is an Amendment, it will be signed by the Investigator.  The 
investigator must submit the Amendment to the IRB/EC for review and approval prior to 
implementation.  Documentation of approval signed by the Chairperson or designee of 
the IRB/EC must be sent to the Sponsor. 
 
If an Amendment substantially alters the study design or increases the potential risk to the 
patient: (1) the consent form must be revised and submitted to the IRB/EC for review and 
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enrolled in the study if they are affected by the Amendment; and (3) the new form must 
be used to obtain consent from new patients prior to enrollment. 
 
All revisions will be sent to the national competent authorities in North America. 
 
12.5.2 Europe 
If the revision is substantial (i.e. likely to have an impact on the safety of the trial subjects 
or to change the interpretation of the scientific documents in support of the conduct of the 
trial or if they are otherwise significant) an amendment application must be submitted to 
the Ethics Committee and the national competent authorities. 
12.6 Retention of Patient Records and Study Files 
CRFs and other reports (e.g., investigator trial files, source documents, original, 
signed/dated informed consent forms) pertaining to this clinical investigation must be 
maintained for a minimum of 2 years following written notification by the sponsor of 
either regulatory approval or discontinuation of the development program.  However, the 
investigator must obtain the Sponsor’s agreement prior to disposal or transfer of 
responsibility for any study-related records. 
 
12.7 Patient Confidentiality 
The sponsor and/or its designee will preserve the confidentiality of all patients taking part 
in this trial. In the event of patient names inadvertently appearing on the trial 
documentation, this information will not be entered into the computer database for this 
trial. Representatives of the sponsor or its designee will seek access to clinical 
information only after approval to do so has been given by the patient and the relevant 
authorities. The data from this trial may be used in company publications and 
submissions to regulatory authorities. 
 
Information about study patients will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act (HIPAA).  
Those regulations require a signed patient authorization informing the patient of the 
following: 
What protected health information (PHI) will be collected from patients in this study 
Who will have access to that information and why 
Who will use or disclose that information 
 
The rights of a research patient to revoke their authorization for use of their PHI:   
In the event that a patient revokes authorization to collect or use PHI, the Investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of 
patient authorization.  For patients that have revoked authorization to collect or use PHI, 
attempts should be made to obtain permission to collect at least vital status (i.e. that the 
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12.8 Informed Consent 
Patients will be required to sign a statement of informed consent that meets the 
requirements of the US Code of Federal Regulations (21 CFR 50), Canadian regulations, 
European Community and European Union National Legislation, local regulations, ICH 
guidelines and the IRB/EC of the study center. The medical record will include a 
statement that written informed consent was obtained before the patient was enrolled in 
the study and the date written consent was obtained. 
 
Members of the treating team will review the nature of the study, its purpose, the 
procedures involved, the expected duration, the potential risks and benefits and 
alternative therapies including best supportive care. Patients must be informed that 
participation in the study is voluntary, he/she may withdraw from the study at any time 
and withdrawal from the study will not affect his/her subsequent medical treatment or 
relationship with the treating physician. Financial costs that will or may be incurred as a 
result of participation in the study, as well as the efforts to maintain patient 
confidentiality will also be discussed. 
 
This consent must be witnessed and dated and retained by the Investigator as part of the 
study records.  A copy of the informed consent form must be given to the patient.  In the 
event the patient is re-screened, the patient is not required to sign another informed 
consent form unless the patient is re-screened more than 30 days from the previous 
informed consent form signature date. 
 
If an Experimental Subject's Bill of Rights is applicable in the Investigator’s US state, 
that form must also be prepared and signed by each patient and retained as a part of the 
required study records.  A copy of the Bill of Rights must be given to the patient or the 
patient's legally authorized representative. 
 
A copy of the IRB approved consent form must be submitted to the Sponsor or its 
designee prior to shipment of drug supplies to the Investigator.  Each patient's signed 
informed consent must be kept on file by the Investigator for regulatory authority and 
Sponsor (or its designee) inspection at any time. 
 
For all US sites, the HIPAA Privacy Rule Authorization language must be included in the 
Informed Consent/authorization form (or a separate authorization document) and 
approved by the IRB (or Privacy Board).  The elements of the HIPAA Privacy Rule 
Authorization are found in APPENDIX 6:  Elements of the HIPAA Privacy Rule 
Authorization. 
 
For all European Union sites the Directive 95/46/EC of the European Parliament and of 
the Council of 24 October 1995 on the protection of individuals with regard to the 
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The Declaration of Helsinki, as amended, recommendations (2008 version), guiding 
doctors in clinical research must be signed by the Investigator and returned to the 
Sponsor or its designee.  A copy must also be kept on file by the Investigator. 
The IRB/EC of an institution must approve the consent form document to be used at that 
center prior to its local activation; changes to the consent form during the course of the 
study will also require IRB/EC notification/approval. 
 
The following elements must appear in the consent form: a description of the purpose of 
the study (indication, that the drug is investigational); potential side effects; potential 
benefits; study design; voluntary participation; and confidentiality.  It is essential that the 
consent form contain a clear statement that gives permission for 1) information to be sent 
to and 2) source medical records to be reviewed by the Sponsor and other agencies as 
necessary. 
 
12.9 Publication Policy 
The results of this study will be published.  Authorship sequence for the final manuscript, 
interim publications and abstracts will be decided by the Sponsor in consultation with all 
investigators.  This will generally be decided according to the number of patients 
accrued.  Each contributing center (and participating investigator) will be acknowledged 
in the final manuscript.  In addition, representatives for the Sponsor may be added, as 
appropriate, as co-authors. 
 
To prevent premature disclosure of proprietary information and to protect the publication 
rights of other investigators in multicenter trials, the Sponsor requires review of written 
and oral presentation at least 45 days prior to initial submission to the publishing 
authority.  If necessary to protect proprietary rights of information to be disclosed in the 
publication, the Sponsor may request a further 45 day delay in submission for 
publication, and the investigators agree to make all reasonable efforts to grant such 
further delay to the Sponsor. 
 
If the investigators have not submitted the results for publication within six months after 
the completion of the final study report, the Sponsor will have the right to publish.  In this 
case, the investigators will be given two months for review and comment prior to 
submission to the publisher. 
 
No participant will present data from his/her study site separately from the rest of the 
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14.0 APPENDIX 1: Patient Evaluation Flow Sheet – Treatment Phase 
Each INDUCTION1 and CONSOLIDATION: 















End of Phase/Early 
Term. 
Informed Consent4 x                 
Medical/Leukemia History x                 
Physical Exam x         x    x   x 
Vital Signs x         x    x   x 
ECOG Performance Status x x                 
ECG x               x x 
Registration & Randomization x                 
Hematology x x  x  x  x x x x x x x x  x 
Biochemistry x x  x  x  x x x x x x x x  x 
Urinalysis x                 
Copper levels x             x9  x  
PK sampling7  x  x  x            
Bone Marrow Evaluation x         x
5 As needed to confirm 
response/persistence 
  
Chest X-ray/Chest CT x                 
Echocardiography/MUGA x             x9  x  
Response Assessment          x6   
Cytogenetics/Molecular Studies x At the time of CR or CRi   
Adverse Events  Assess throughout Induction and Consolidation x  
Concomitant Medications  Assess throughout Induction and Consolidation x  
ARM A: CPX-351 x  x  x2            
OR 
Cytarabine x x x x x x2 x2          
Treatment 
Administration 
ARM B: Daunorubicin x x x2              
1The first induction may end prematurely if a second induction is necessary, see Section 4.6.  The schedule of evaluations for the first induction is followed until the second induction starts, then the 
evaluations are followed as indicated in the flow sheet, beginning with Day 1 
2 Second inductions and consolidations of ARM A are CPX-351 on Days 1 and 3 and ARM B is 5 days of cytarabine and 2 days of daunorubicin, see Sections 4.6 & 4.7
3Continue weekly evaluations until confirmation of response (CR/CRi) or persistent disease is declared 
4 Within 30 days prior to start of screening, if informed consent was collected, 30 days elapse and the patient is still not screened he/she must sign another ICF 
5Required after each induction; (in case the Day 14 bone marrow is non-evaluable or assessment of aplasia is equivocal, a repeat evaluation may be performed 5-14 days later, at the discretion of the 
treating physician, in order to determine effect and need for second induction);  as needed thereafter to confirm response/persistence/relapse in second inductions & consolidations 
6Induction(s) only; see Section 8.4.1 for details on when response is assessed. 
7CPX-351 patients will be randomized to one of two PK sampling schedules:  See Section 6.2 for the timing of pK draws 
8Day 150 or 45 Days after the last treatment whichever is later 
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15.0 APPENDIX 2: Patient Evaluation Flow Sheet –Follow-up 





Patient status report x x x 
Hematology x  x 
Biochemistry Perform monthly only if abnormality(ies) 
persists at the end of the Treatment Phase.  
Perform until abnormality(ies) returns to 
baseline, until 1 year from randomization, 
or the initiation of new therapy and/or 
relapse. (which ever is earliest) 
  
Copper levels If elevated copper (>20% above ULN) 
persists at Day 150 perform monthly until 
abnormality returns to baseline or until 1 




For patients in CR or CRi perform at any time that there is a suspicion of relapse. For 
patients in CR, perform if peripheral blood counts fall below 1000/μL for ANC or 
100,000/μL for platelets for >1 month or at any time there is suspicion of relapse. For 
patients in CRi perform if counts fall significantly below peak recovery levels.  If the 
peripheral blood counts in a patient with a CRi recover to CR levels (≥1000/μL for ANC 
or ≥100,000/μL for platelets), perform a bone marrow evaluation within 14 days to 
confirm CR.  Following the first year of follow up, record relapse information, including 
any bone marrow evaluations.  Not required following the initiation of new therapy and 
or relapse. 
Echocardiography or MUGA 
scan 
If last LVEF was reduced >10% from 
baseline and is less than 50% repeat every 3 
months until LVEF returns to baseline or 
until 1 year from randomization.  Persistent 
reductions in LVEF of >10% and failing 
below 50% lasting >1 year are considered 
permanent sequelae. 
  
  Assess AEs that were ongoing at the time 
of discontinuation. Do NOT record any 
new AEs.  AEs that persist without 
evidence of recovery for >30 days are 
considered permanent sequelae and do not 
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16.0 APPENDIX 3: WHO Classification of Secondary Acute Myeloid Leukemia18 
The eligible patient population based on WHO: 
 
Therapy related AML: 
Requires more than 20% blood or marrow blasts AND prior cytotoxic therapy for an unrelated disease: 
• alkylating agents 
• ionizing radiation therapy: large fields including active bone marrow 
• topoisomerase II inhibitors 
• others: antimetabolites, antitubulin agents 
 
Acute myeloid leukemia with myelodysplasia-related changes: 
Requires more than 20% blood or marrow blasts AND any of the following: 
1. Previous history of myelodysplastic syndrome (MDS)requires: 
Bone marrow evidence of dysplasia present 
in ≥10% of cells in one or more myeloid 
lineages or ≥10% dysplastic 
megakaryotypes 
AND/OR 
Unequivocal dysplasia in <10% of cell in one 
or more myeloid cell lines with clonal 
abnormalities characteristic of MDS1 
1Clonal abnormalities:  Unbalanced changes:+8*, -7 or del(7q), -5 or del(5q); del(20q)*, -Y*, i(17q) or 
t(17p), -13 or del(13q), del(11q), del(12p) or t(12p), del(9q), idic(X)(q13) Balanced changes: 
t(11;16)(q23;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); t(2;11)(p21;q23); inv(3)(q21q26.2), 
t(6:9)(p23;q34) 
*If the sole cytogenetic abnormality, also needs morphologic criteria with dysplasia present in ≥10% of 
cells in one or more myeloid lineages or ≥10% dysplastic megakaryotypes; all other clonal abnormalities 
are sufficient for a presumptive diagnosis 
OR 
2. With myelodysplastic syndrome-related cytogenetic abnormalities: 
o Complex karyotype (defined as 3 or more chromosomal abnormalities). 
o Unbalanced:  -7 or del(7q); -5 or del(5q); i(17q) or t(17p); -13 or del(13q); del(11q); 
del(12p) or t(12p); del(9q); idic(X)(q13). 
o Balanced:  t(11;16)(q23;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); 
t(2;11)(p21;q23), t(5;12)(q33;p12); t(5;7)(q33;q11.2); t(5;17)(q33;p13); t(5; 
10)(q33;q21); t(3;5)(q25;q34) 
 
AML with a history of CMMoL: 
Requires more than 20% blood or marrow blasts AND a history of CMMoL which requires: 
• Peripheral blood monocytosis >1000/μL 
• Absence of Philadelphia chromosome or BCR-ABL1 fusion gene 
• In the presence of eosinophilia, absence of rearrangements of PDGFRA or PDGFRB 
• Presence of dysplasia in one or more myeloid lineages 
• If myelodysplasia is absent/minimal the diagnosis of CMMoL may still be made if the above 
requirements are met and in addition there is the: 
o presence of acquired clonal cytogenetic or molecular genetic abnormality in 
hematopoietic cells OR 
o persistence of monocytosis for ≥3 months and 
o all other causes of monocytosis have been excluded 
• At diagnosis of CMMoL there are fewer that 20% blasts (myeloblast, monoblast, promonocytes) 
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17.0 APPENDIX 4: Performance Status – ECOG 
 
Grade Description 
0 Fully active, able to carry on all pre-disease performance without restriction (Karnofsky 90-100) 
1 
Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature (e.g., light housework, office work) 
(Karnofsky 70-80). 
2 Ambulatory and capable of all self-care but unable to carry out any work activities.  Up and about more than 50% of waking hours (Karnofsky 50-60). 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours (Karnofsky 30-40). 
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18.0 APPENDIX 5: Common Terminology Criteria for Adverse Events V3.0 
(CTCAE) 
 
This 72 page document can be obtained as a pdf file from http://ctep.cancer.gov. 
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19.0 APPENDIX 6:  Elements of the HIPAA Privacy Rule Authorization 
• Written in plain language understandable to the patient or the representative; 
• A “specific and meaningful” description of Protected Health Information (PHI) to 
be used and disclosed; 
• The specific identification of the person/class authorized to make the use or 
disclosure; 
• The specific identification of the persons/class to whom the covered entity may 
make the requested use or disclosure; 
• Description of the purpose of the disclosure; 
• An expiration date or event (i.e., “no expiration date” for data repository use, or 
“for the duration of a specific research study” permits use until end of study plus 
time for wrapping up and reporting); 
• A statement of the patient’s right to revoke the authorization and any exceptions 
to the right to revoke; 
• Conditions, if any, on authorization; 
• A statement about possible re-disclosures of PHI by the recipient and that the PHI 
will no longer be protected by the Privacy Rule in the event of such re-
disclosures; and 
• The signature and date of the patient (or of the patient’s personal representative, 
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20.0 APPENDIX 7:  Declaration of Helsinki 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI ETHICAL PRINCIPLES FOR 
MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS 
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21.0 APPENDIX 8: Anthracyclines Equivalents Guidelines 
According to the exclusion criteria patients with a total lifetime anthracycline exposure 
exceeding the equivalent of 368 mg/m2 of daunorubicin (or equivalent) prior to start of 
study therapy [100 u/m2 of CPX-351 contains 44 mg/m2 of daunorubicin x 3 doses (1 
induction) = 132 mg/m2 + 368 mg/m2 = 500 mg/m2 = maximum allowable limit of 
daunorubicin from all sources at the end of the 1st induction] are excluded from Protocol 
CLTR0310-301.  
 











200mg/m2 of mitoxantrone x 4.4(conversion factor) = 880mg/m2  
This means 200mg/m2 of mitoxantrone is equivalent to 880 mg/m2 of daunorubicin  
 
*Adapted from Keefe D., Anthracycline-Induced Cardiomyopathy. Seminars in 
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1.0 List of Abbreviations 
Abbreviation Full Term 
7+3 Seven days of continuous infusion of cytarabine at 100 mg/m
2/day and 
three days of daunorubicin at 60 mg/m2/day 
AE Adverse Event 
AML Acute Myeloid Leukemia 
ANC Absolute Neutrophil Count 
BSA Body Surface Area 
CMMoL Chronic Myelomonocytic Leukemia 
CPX-351 CPX-351 (cytarabine: daunorubicin) Lipisome Injection 
CR Complete Response 
CRF Case Report Form 
CRi Complete Response with incomplete hematologic recovery 
DSMB Data and Safety Monitoring Board 
ECG Electrocardiogram 
ECOG Eastern Cooperative Oncology Group 
EFS Event-free Survival 
HSCT Hematopoietic Stem Cell Transplantation 
ITT Intent-to-treat 
m2 square meters 
MDS myelodysplastic syndrome 
MedDRA Medical Dictionary for Regulatory Activities 
mg milligram(s) 
µL microliter(s) 
MLS Morphologic Leukemia-free State 
OS Overall Survival 
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PK Pharmacokinetics 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SOP Standard Operating Procedure 
t-AML Therapy-related AML 
WHO World Health Organization 
 
2.0 Introduction 
This Statistical Analysis Plan (SAP) describes the proposed statistical analysis of the study 
entitled: “Phase III, multicenter, randomized, trial of CPX-351 (Cytarabine: Daunorubicin) 
liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with 
untreated high risk (secondary) AML.”  
 
The purpose of this document is to ensure the credibility of the study outcomes by pre-
specifying the statistical approaches and data handling conventions for key analyses.  This plan 
will focus on the analysis of the primary endpoints, which are overall survival (OS) and the 
safety of CPX-351, and the secondary endpoints, which are response, event-free survival 
(EFS), additional CPX-351 safety measures, pharmacokinetics (PK), and pharmacoeconomics. 
The primary analyses of all endpoints will be described, the populations for analysis defined, 
and all of the rules specified for “data handling” relevant to undertaking the key analyses. 
 
Some assumptions in this analysis plan are based on a prior Phase II study, Protocol 
CLTR0308-204 (“Study 204”), which enrolled newly diagnosed AML patients 60-75 years of 
age. 
 
3.0 Study Objectives and Endpoints 
3.1 Overview of Study 
This study is an open-label, randomized Phase III study, where newly diagnosed AML 
patients (including t-AML, AML in patients with a history of MDS or CMMoL, and de 
novo AML in patients with specific adverse karyotypic changes (per WHO definitions)) 
are randomized with equal allocation to receive either CPX-351 (Study Arm A) or 
cytarabine + daunorubicin (7+3 regimen) (Study Arm B).  A total of 240 patients will 
be accrued and randomized to obtain 220 evaluable patients. Patients are stratified by 
age and AML subtype at randomization to balance these prognostic factors across 
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number of patients to each of the treatment regimens. The procedure will balance the 
marginal distribution of the stratification factors between these treatment regimens. 
3.1.1 Stratification and Randomization Scheme 
At registration, patients will be randomized to receive either CPX-351 (Study 
Arm A) or cytarabine + daunorubicin (7+3 regimen) (Study Arm B). Only 
patients determined to be eligible following a pathological diagnosis of AML 
according to WHO criteria (with at least 20% blasts in the peripheral blood or 
bone marrow) and confirmation of secondary AML by WHO criteria will be 
randomized (Appendix 1.)  Patients will be stratified on the following factors:  
Strata  
Age Age 60-69 years 
OR 
Age 70-75 
AML Type • Therapy-related AML: t-AML 
• MDS transformed to AML with prior HMA treatment: MDSAML 
• MDS transformed to AML without prior HMA treatment: MDSAML 
• CMMoL transformed to AML: CMMoLAML 
• De novo AML with MDS karyotype: de novoAML 
 
3.1.2 Dynamic Randomization Algorithm 
 
A dynamic balancing randomization algorithm will be used to ensure that the 
assignment of treatments is balanced across all the stratification factors. This 
procedure balances the marginal distribution of the stratification factors between 
these treatment regimens. The approach used is based on the method described 
by Pocock and Simon (Pocock and Simon, 1975). 
 
3.2 Study Objectives: Primary 
• To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly 
patients (60-75 years) with secondary AML. The primary efficacy endpoint will be 
OS. 
• To confirm the safety of CPX-351 
3.3 Study Objectives: Secondary 
• To confirm the improvement in achievement of morphologic leukemia free state 
(MLS), post-induction response (CR+CRi) rate, remission duration (relapse-free 
survival), EFS and overall best response (CR+CRi) rate following CPX-351 
• To confirm the safety and practicality of CPX-351 as consolidation therapy 
• To assess serum copper elevations 
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• To assess and compare the pharmacoeconomic differences between CPX-351 and 
control 
3.4 Clinical Trial Endpoints 
3.4.1 Overall Survival (OS) 
All randomized patients are assessed for OS.  Overall survival is measured from 
the date of randomization to death from any cause.  Patients not known to have 
died at last follow-up are censored on the date they were last known to be alive. 
Patients will be followed for a minimum of 2 years. 
3.4.2 Event-free Survival (EFS) 
All randomized patients are assessed for EFS. Event-free survival is defined as 
the time from study randomization to the date of induction treatment failure 
(persistent disease), relapse from CR or CRi or death from any cause, whichever 
comes first.  Patients alive and not known to have any of these events are 
censored on the date they were last examined. 
3.4.3 Response Assessment Criteria 
During the Treatment Phase patients will be assessed for response according to 




Bone marrow blasts <5%; absence of blasts with Auer rods; 
absence of extramedullary disease; absolute neutrophil count 
>1.0 x 109/L (1000/μL); platelet count >100 x 109/L 




All CR criteria except for residual neutropenia (<1.0 x 109/L 
[1000/μL]) or thrombocytopenia (<100 x 109/L [100,000/μL]) 




Failure to achieve CR or CRi; only includes patients surviving 
≥7 days following completion of initial treatment, with 
evidence of persistent leukemia  (blasts in peripheral blood, 
extramedullary leukemia, or persistence in the bone marrow) 
Death in aplasia Deaths occurring ≥7 days following completion of initial 
treatment while cytopenic; with an aplastic or hypoplastic 
bone marrow obtained within 7 days of death, without 




Deaths occurring before completion of therapy, or <7 days 
following its completion; or deaths occurring ≥7 days 
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blood, but no bone marrow examination available at recovery 
Relapse3 Bone marrow blasts ≥5%; or reappearance of blasts in the 
blood after achievement of a CR or CRi; or development of 
extramedullary disease 
1Bone marrow assessment REQUIRED to confirm CR. All criteria need to be fulfilled; marrow 
evaluation should be based on a count of 200 nucleated cells in an aspirate with spicules; if 
ambiguous, consider repeat exam after 5 to 7 days; flow cytometric evaluation may help to 
distinguish between persistent leukemia and regenerating normal marrow; a marrow biopsy 
should be performed in cases of dry tap, or if no spicules are obtained; no minimum duration of 
response required. 
2 Bone marrow assessment REQUIRED to confirm CRi. Some patients may not achieve 
complete hematologic recovery prior to initiation of consolidation.  CRi cannot be declared 
earlier than Day 35 to allow adequate time for documentation of peripheral blood recovery.  
Consolidation may begin no earlier than 42 days after the last induction course. 
3In cases with low blast percentages (5-10%), a repeat marrow should be performed to confirm 
relapse. Appearance of new dysplastic changes should be closely monitored for emerging 
relapse. In a patient who has been recently treated, dysplasia or a transient increase in blasts 
may reflect a chemotherapy effect and recovery of hematopoiesis. 
 
The response of patients with no post-baseline bone marrow assessment is 
entered as not done. 
3.4.3.1 Timing of response assessment 
In general, the patient’s response to induction therapy is made on the 
first day when all criteria for CR or treatment failure are met.  The bone 
marrow assessment and the peripheral counts are not required to be 
performed on the same day but recovery of counts (including absence of 
peripheral blasts) must be performed within 14 days of the bone marrow 
assessment.  The timing of other outcomes is recorded as follows: 
 
After one or two induction course(s), PD is declared on the day of the 
bone marrow showing persistent AML. 
 
CRi is declared on or after Day 35 when the patient’s bone marrow 
(performed between day 35-56) demonstrates absence of leukemia and 
the peripheral blood counts have partially recovered but appear stable 
(performed at least twice between day 42-56) and no further therapy is 
anticipated.  
 
For patients with sufficient blood count recovery (ANC ≥500/μL and 
platelets ≥50,000/μL) that consolidation therapy is planned, CRi is 
declared on the day consolidation therapy is initiated but the peripheral 
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3.4.3.2 Best Response 
Patients who complete the induction(s) with a response of CRi may be 
upgraded to a CR during or after consolidation if the patient’s peripheral 
blood counts meet the criteria for CR after declaration of a CRi.  To 
upgrade a response to CR both peripheral blood and bone marrow 
assessment must be obtained within a 14 day period of each other and all 
criteria for CR must be met (within a 14 day period must have full 
recovery AND be leukemia- free). 
3.4.4 Remission Duration 
Only patients achieving CR or CRi are assessed for remission duration (relapse-
free survival). Remission duration is measured from the date of achievement of 
a remission (CR/CRi) until the date of relapse or death from any cause; patients 
not known to have relapsed or died at last follow-up are censored on the date 
they were last examined. 
3.4.5 Morphologic Leukemia-free State (MLS) 
All randomized patients that have at least one evaluable post-randomization 
bone marrow assessment are assessed for MLS.  Morphologic leukemia-free 
state is defined as bone marrow blasts <5% AND absence of Auer rods and/or 
extramedullary disease. 
3.4.6 Stem Cell Transplant (HSCT) 
The number and percentage of patients transferred for HSCT will be 
quantitated and compared. 
3.4.7 Safety Endpoints 
Safety data will be analyzed and reported for all patients in the safety population 
as defined in section 4.2. Safety endpoints will include hematology, coagulation, 
chemistries, urinalysis, vital signs, ECG, echocardiography and adverse events 
(AEs).  AEs will be coded using the MedDRA coding dictionary.  Laboratory 
values will be summarized both by actual result and by toxicity grade (when 
available).   
 
4.0 Populations For Analysis 
Figure 4-1 describes the respective patient populations being defined for the study in a flow 
chart format. 
















Cancer Research And Biostatistics 
 
CLTR0310-301 Statistical Analysis Plan 
 
 
Version 1.0 22 May 2012 Page 10 of 33 
 
Copyright 2007 Cancer Research And Biostatistics (CRAB®).  All Rights Reserved.  Confidential. 
 
The ITT population is all patients who have been randomized to the trial. Patients are 
assigned to treatment arms based on what they were “randomized” to receive. This is 
the primary efficacy population. 
4.2 Safety Population 
All patients who receive at least one dose of study medication (CPX-351, cytarabine or 
daunorubicin), regardless of eligibility, and have at least one post-baseline safety 
follow-up. Safety will be analyzed using the safety population. Patients are assigned to 
treatment arm based on what they receive.  
4.3 Per Protocol Population (PPP) 
These patients are a subset of the ITT population. The PPP includes all patients who 
have met inclusion/exclusion criteria and have received at least one dose. The analysis 
of transfer to HSCT will be performed on this study population.  
4.4 Morphologic Leukemia-free State (MLS) Population 
These patients are a subset of the per-protocol population. The MLS population 
includes all patients who have met inclusion/exclusion criteria, have received at least 
one dose and have at least one evaluable post-randomization bone marrow assessment 
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? CR/CRi rate 
? CR/CRi duration 
PPP 
Randomized, eligible, and have received 
at least one dose: 
? OS 
? EFS 
? CR/CRi rate 
? CR/CRi duration 
Safety Population  
Randomized and have received at least 
one dose of study medication: 
? 30/60 Day Mortality 
? SAEs 
? Grade ≥3 AE 
? AE frequency (grade 1-5) 
? Special AE categories: 
o Infection 
o Bleeding Events 
o Cardiac Events 
o GI Events 
? Labs MLS Population 
Randomized, eligible, and have received at 
least one dose and have at least one evaluable 
post-randomization bone marrow assessment: 
? MLS 
 
Screened and Randomized 
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5.0 Statistical Methods and Determination of Sample Size 
5.1 Determination of Sample Size 
5.1.1 Primary Efficacy Endpoint 
The study will accrue 220 evaluable patients (110 per arm). An additional 20 
patients (10 per arm) will be accrued to account for ineligible patients and 
patients withdrawing consent.  All sample size and power justifications are 
based on evaluable patients only and will be referred to as “patients” 
throughout the remainder of the statistical analysis plan. Assuming a uniform 
recruitment of 135 patients per year, 1.65 years will be required to complete 
enrollment of 220 patients. Furthermore, patients will be followed until the last 
patient enrolled has been followed for 1.2 years.  Assuming exponential 
survival, and a median OS of 6 months in the control arm (Arm B), 190 deaths 
are expected to occur after opening of the study, resulting in a study with 94% 
power and a one-sided significance level alpha of 0.025 to detect a hazard ratio 
of 0.6 between the two treatment arms.  Total time for study completion is 
approximately 2.85 years. 
 
A hazard ratio of 0.41 was observed in the 204 study for sAML patients. This 
study is designed to have 94% rather than 90% power for the primary endpoint 
to assure that the sensitivity analysis which accounts for potential early drop-
outs due to transplant is adequately powered to 90% for the same hazard ratio 
of 0.6 and the same patient population. Please see section 5.1.3 for details on 
this sensitivity analysis. 
 
5.1.2 Secondary Efficacy Endpoint 
In the 204 study the observed hazard ratio for event-free survival of the 7+3 
arm versus the CPX-351 arm was 1.79 (0.56) in the patient population with 
secondary AML. The observed median event-free survival in the control arm 
was 42 days. This trial design with 220 patients total accrued over a period of 
1.65 years with a 1.2 year follow-up yields 99% power and a one-sided 
significance level alpha of 0.025 to detect a hazard ratio of 1.79 (0.56) between 
arms. This same trial design yields 90% power (with a one-sided significance 
level of 0.025) to detect a hazard ratio of 1.55 (0.645). These calculations are 
based on the assumption that the events are exponentially distributed. 
 
In the 204 study the observed response rate (CR+CRi) in secondary AML 
patients was approximately 58% in the CPX-351 arm and 32% in the 7+3 arm. 
This trial design with a total of 220 patients yields 97% power and a one-sided 
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the CPX-351 arm. These calculations are based on the assumption that the 
responses are binomially distributed and that the response rate in the control 
arm (7+3) is 32%. Based on those same assumptions, this trial design with 220 
patients yield 91% power to detect a difference in responses of 23% (32% 
versus 55%). 
5.1.3 Sensitivity Analyses 
In the 204 study approximately 19% of patients had HSCT. A sensitivity 
analysis will be performed comparing overall survival in the two arms with 
patients censored at the time of transplant. This analysis will account for early 
drop-out due to transplant and will be performed on the ITT population. To 
minimize imbalances between arms due to transplant, stratification by age (see 
Section 3.1.1) will be used.  
 
We assume the same design considerations as for the sample size calculations 
for the primary endpoint: 220 patients accrued in 1.65 years, followed for 1.2 
years, median OS in control group 6 months. Using these design considerations 
and assuming a constant drop-out rate in the first year after enrollment due to 
transplant with a cumulative drop-out of 20% in each arm, which corresponds 
to a hazard rate of the competing transplant risk of 0.223, yields a study with 
90% power (and a one-sided alpha of 0.025) to detect a hazard ratio of 0.60. 
We also examined the extreme cases of maximum imbalance between arms, 
when all drop-outs due to transplant occur in just one treatment arm. Using the 
same assumptions as outlined above, but assuming a constant drop-out rate in 
the first year with a cumulative drop out of 40% due to transplant in the CPX-
351 arm and no drop-out in the 7+3 arm still yields a study with 90% power 
(and a one-sided alpha of 0.025) to detect a hazard ratio of 0.60. Likewise, 
assuming a constant drop-out rate in the first year with a cumulative drop out of 
40% due to transplant in the 7+3 arm and no drop-out in the CPX-351 arm still 
yields a study with 90% power (and a one-sided alpha of 0.025) to detect a 
hazard ratio of 0.60.  
5.2 Data and Safety Monitoring Board (DSMB) 
A data and safety monitoring board (DSMB) will be appointed and will be responsible 
for safeguarding the interests of trial participants, assessing the safety and efficacy of 
the clinical trial intervention during the trial, and for monitoring the overall conduct of 
the trial.  The DSMB will periodically monitor the ongoing study for safety and efficacy 
considerations. The DSMB will consist of independent reviewers who are not directly 
involved in the conduct of the study and will advise the Sponsor of any trends or safety 
issues which may impact the study and/or the study patients.  The DSMB will operate 
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• Consist of 2 hematologists + 1 cardiologist + 1 statistician + 1 clinical operations 
assistant 
• Hold at least five meetings: Before the study starts, at 25%, 50%, 75% of accrued 
patients and at end of study to review day 60 deaths and SAEs 
• Conduct a single analysis after 60 patients (30 per arm) have been evaluated for 
induction mortality.  Study stops if the 60 day death rate in either arm is 
unacceptable as determined by the DSMB. 
• A charter will be reviewed and ratified prior to the initiation of the study 
5.3 Statistical Methods 
5.3.1 Demographic and Baseline Comparisons 
 Demographics 
Demographic characteristics will be summarized for all analysis populations as 
defined in section 4.0 (ITT population, safety population, PPP, and MLS 
population.)  The total counts and percentages of patients will be presented for 
the categorical variables, both overall and by treatment arm (Table 1 in 
Appendix 3.)  The mean, median, standard deviation, and range, will be 
presented for continuous variables, both overall and by treatment arm (Table 2 
in Appendix 3.)  Age in years (defined as the date of signed informed consent 
minus the date of birth divided by 365.25 days truncated to the lowest integer) 
will be summarized as both a continuous variable and categorical variable, with 
grouping done as 60-69 years and 70-75 years. 
Baseline Patient Characteristics   
The following patient characteristics will be collected at the Pre-Study visit 
and/or pre-dose: height; weight; BSA; ECOG Performance Status; vital signs; 
laboratory evaluations (including serum copper test); 12-lead ECG; and 
physical examination. 
The Pre-Study visit will occur within 14 days prior to randomization. Baseline 
values for vital signs are defined as the last recorded values prior to first dose of 
study drug. For physical examination findings, baseline is defined as the last 
value for each body system prior to receiving the first dose of study drug.  
Baseline characteristics will also be summarized for all analysis populations as 
defined in section 4.0 (ITT population, safety population, PPP, and MLS 
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the categorical variables, both overall and by treatment arm (Table 1 in 
Appendix 3.)  The mean, median, standard deviation, and range will be 
presented for continuous variables, both overall and by treatment arm (Table 2 
in Appendix 3.) 
5.3.2 Patient Disposition 
The numbers and percentages of patients who were registered (randomized) and 
who are included in the safety and efficacy analysis sets will be summarized, 
both overall and by treatment arm (Table 3 in Appendix 3.)  Patients who were 
not registered will not be collected in the CRF, not included in the database, and 
not presented.  
The number and percentages of patients who discontinued from the study and 
the reason for termination will also be presented, both overall and by treatment 
arm (Table 3 in Appendix 3.)    
The treatment group, date of randomization, date of first dose, date of last dose, 
date of termination, and reason for termination will be listed for each patient 
who discontinues from the study (Table 4 in Appendix 3.) 
5.3.3 Efficacy Analysis 
5.3.3.1 Primary Endpoint Analysis 
Primary efficacy analyses will be performed for the ITT population.  
According to the ITT principle, patients will be included in the analysis 
according to the randomized treatment assignment, regardless of the 
actual treatment received.  For the primary endpoint analysis, a stratified 
log-rank test (Mantel, 1966) will be used to compare the experimental 
arm (CPX-351) to the control arm (“7+3”) (Table 5 in Appendix 3.).  
The test will be stratified by the stratification factors defined in section 
3.1.  The analysis for the primary endpoint will be performed after 190 
deaths (86%) have occurred. Assuming exponential survival, uniform 
recruitment of 135 patients per year, an accrual period of 1.65 years, an 
additional follow-up period of 1.2 years and a median OS of 6 months, 
190 events are expected to occur within 2.85 years after the opening of 
the study.  The number of events is based on the alternative hypothesis.   
 
In addition, the distribution of OS in each arm will be estimated using 
the method of Kaplan-Meier (Kaplan and Meier, 1957) by treatment 
group.  The Kaplan-Meier method will be used to obtain estimates for 
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presented by treatment arm, with a median presented for each arm and a 
95% confidence interval around each median time (Figure 1 in Appendix 
3.)   
 
A Cox proportional hazard regression analysis (Cox, 1972) will be 
performed to determine which prognostic factors are associated with OS.  
A univariate Cox regression analysis will be performed for all prognostic 
factors, and the resulting hazard ratios, 95% confidence intervals, and p-
values will be reported (Table 6 in Appendix 3.)  Patients for whom data 
for a specific prognostic factor is not available will be excluded from the 
univariate analysis for that variable. 
 
Exploratory multivariate analyses will be performed to assess the effect 
of treatment in the presence of other key prognostic factors.  A 
multivariate Cox regression model will be run (Table 6 in Appendix 3) 
including a variable indicating treatment arm, allowing selection of other 
prognostic factors to see if the treatment effect is significant in the 
presence of other prognostic factors.  Patients who do not have data 
available for all prognostic factors considered for selection in the 
multivariate model will be excluded from the multivariate analysis. 
 
5.3.3.2 Secondary Endpoint Analysis 
Secondary efficacy endpoints include overall post induction response 
(CR+CRi) rate, best response (CR+CRi) rate (after completion of the 
treatment phase), remission duration and EFS as defined in Section 3.4.   
 
Secondary endpoints also include the rate of MLS and the rate of transfer 
for HSCT. 
 
All efficacy analyses will be performed on an ITT basis using the ITT 
analysis population.  
 
Time dependent endpoints  
 
For the secondary time dependent endpoints (remission duration and 
EFS), a stratified log-rank test (Mantel, 1966) will be used to compare 
the experimental arm (CPX-351) to the control arm (7+3.) (Table 5 in 
Appendix 3.)  In addition, the distribution of these endpoints (remission 
duration and EFS) in each arm will be estimated using the method of 
Kaplan-Meier (Kaplan and Meier, 1957) by treatment group.  Kaplan-
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presented for each arm and a 95% confidence interval around each 
median time (Figure 1 in Appendix 3.)   
 
A Cox proportional hazard regression analysis (Cox, 1972) will be 
performed to determine which prognostic factors are associated with 
these time-dependent endpoints (remission duration and EFS.)  A 
univariate Cox regression analysis will be performed for all prognostic 
factors, and the resulting hazard ratios, 95% confidence intervals, and p-
values will be reported (Table 6 in Appendix 3.)  Patients for whom data 
for a specific prognostic factor is not available will be excluded from the 
univariate analysis for that variable. 
 
Exploratory multivariate analyses will be performed to assess the effect 
of treatment in the presence of other key prognostic factors.  A 
multivariate Cox regression model will be run (Table 6 in Appendix 3) 
including a variable indicating treatment arm, allowing selection of other 
prognostic factors to see if the treatment effect is significant in the 
presence of other prognostic factors.  Patients who do not have data 
available for all prognostic factors considered for selection in the 




The response (CR+CRi) rate and best response (CR+CRi) rate will be 
calculated based on the responses achieved as defined in section 3.4.3, 
with counts and percentages both overall and by treatment arm 
summarized (Table 7 in Appendix 3.)  The number of patients who 
achieve a CR or CRi will be divided by the number of patients in the ITT 
analysis population.  
 
Likewise, the rate of achieving a MLS will be calculated as the number 
of patients who develop this state, as defined in section 3.4.5, divided by 
all randomized patients who have at least one evaluable post-
randomization bone marrow assessment performed on Day 14-21 after 
the last induction.  The MLS rate will also be summarized with counts 
and percentages, both overall and by treatment arm (Table 7 in Appendix 
3.) 
 
The rate of transfer for SCT will be calculated by the number of patients 
starting conditioning treatment for SCT divided by the number of 
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summarized with counts and percentages, both overall and by treatment 
arm (Table 7 in Appendix 3.) 
 
The difference in response rate, MLS rate, and rate of transfer for HSCT 
between the two treatment arms will be calculated using the Mantel-
Haenszel test (Mantel and Haenszel, 1959). These comparisons will be 
stratified by the stratification factors specified in section 3.1. 
 
A logistic regression analysis (Hosmer and Lemeshow, 2000) will also 
be performed to determine which prognostic factors are associated with 
these binary endpoints (response rate, best response rate, MLS rate, and 
HSCT rate.)  A binary variable indicating whether a patient achieved 
response, best response, MLS, or HSCT will serve as the dependent 
variable in these analyses, respectively. 
 
A univariate logistic regression analysis will be performed for all 
prognostic factors, and the resulting odds ratios, 95% confidence 
intervals, and p-values will be reported (Table 8a-d in Appendix 3.)  
Patients for whom data for a specific prognostic variable is not available 
will be excluded from the univariate analysis for that variable. 
 
Additionally, exploratory multivariate analyses will be performed to 
assess the effect of treatment in the presence of other key prognostic 
factors.  A multivariate logistic regression model will be run (Table 8 in 
Appendix 3) including a variable indicating treatment arm, allowing 
selection of other prognostic factors to see if the treatment effect is 
significant in the presence of other prognostic factors.  Patients who do 
not have data available for all prognostic factors considered for selection 
in the multivariate model will be excluded from the multivariate 
analysis. 
5.3.3.3 Patient Population for Efficacy Analyses 
All main analyses will be based on the ITT principle; all randomized 
patients are evaluable for efficacy.  Patients that die on or before Day 7 
will be replaced. 
 
The primary and secondary efficacy endpoint analyses described in 
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5.3.3.4 Sensitivity Analysis for Effects of Transplant on OS 
A sensitivity analysis will be performed to assess the potential bias due 
to early drop-out due to transplant.  The sensitivity analysis will be 
performed on the ITT population.  For this analysis, patients will be 
censored at time of transplant.  The same analyses as for the primary 
efficacy endpoint (section 5.3.3.1) will be performed, but with survival 
times censored at time of transplant for patients receiving transplant. 
 
A stratified log-rank test (Mantel, 1966) will be used to compare the 
experimental arm (CPX-351) to the control arm (“7+3”).  The 
distribution of OS in each arm will be estimated using the method of 
Kaplan-Meier (Kaplan and Meier, 1957) by treatment group.  The 
Kaplan-Meier method will be used to obtain estimates for the 
probabilities of patients surviving.  Kaplan-Meier curves will be 
presented by treatment arm, with a median presented for each arm and a 
95% confidence interval around each median time (Figure 1 in Appendix 
3.)   
 
A Cox proportional hazard regression analysis (Cox, 1972) will be 
performed to determine which prognostic factors are associated with OS.  
A univariate Cox regression analysis will be performed for all prognostic 
factors, and the resulting hazard ratios, 95% confidence intervals, and p-
values will be reported (Table 6 in Appendix 3.)  Patients for whom data 
for a specific prognostic factor is not available will be excluded from the 
univariate analysis for that variable. 
 
Exploratory multivariate analyses will be performed to assess the effect 
of treatment in the presence of other key prognostic factors.  A 
multivariate Cox regression model will be run (Table 6 in Appendix 3) 
including a variable indicating treatment arm, allowing selection of other 
prognostic factors to see if the treatment effect is significant in the 
presence of other prognostic factors.  Patients who do not have data 
available for all prognostic factors considered for selection in the 
multivariate model will be excluded from the multivariate analysis. 
 
Results from the sensitivity analysis can then be reviewed side-by-side 
with the results from the primary efficacy endpoint analysis to assess the 
effect of early drop-out due to transplant on the results.  
5.3.3.5 Sensitivity Analysis for Effects of Transplant on EFS 
A sensitivity analysis will also be performed to assess the potential bias 
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will be performed on the ITT population.  For this analysis, survival 
times will be censored at time of transplant for patients receiving 
transplant.  Patients who progress or relapse on or before the day of 
transplant will still be counted as events, but patients who have not 
progressed or relapsed will be censored at time of transplant.  The same 
analyses as for the secondary efficacy EFS endpoint (section 5.3.3.2) 
will be performed. 
 
A stratified log-rank test (Mantel, 1966) will be used to compare the 
experimental arm (CPX-351) to the control arm (“7+3”.)  The 
distribution of EFS in each arm will be estimated using the method of 
Kaplan-Meier (Kaplan and Meier, 1957) by treatment group.  Kaplan-
Meier curves will be presented by treatment arm, with a median 
presented for each arm and a 95% confidence interval around each 
median time (Figure 1 in Appendix 3.)   
 
A Cox proportional hazard regression analysis (Cox, 1972) will be 
performed to determine which prognostic factors are associated with 
EFS.  A univariate Cox regression analysis will be performed for all 
prognostic factors, and the resulting hazard ratios, 95% confidence 
intervals, and p-values will be reported (Table 5 in Appendix 3.)  
Patients for whom data for a specific prognostic factor is not available 
will be excluded from the univariate analysis for that variable. 
 
Exploratory multivariate analyses will be performed to assess the effect 
of treatment in the presence of other key prognostic factors.  A 
multivariate Cox regression model will be run (Table 5 in Appendix 3) 
including a variable indicating treatment arm, allowing selection of other 
prognostic factors to see if the treatment effect is significant in the 
presence of other prognostic factors.  Patients who do not have data 
available for all prognostic factors considered for selection in the 
multivariate model will be excluded from the multivariate analysis. 
 
Results from the sensitivity analysis can then be reviewed side-by-side 
with the results from the secondary efficacy endpoint analysis to assess 
the effect of early drop-out due to transplant on the results. 
 
5.4 Details Outlining Data Quality of Formal Analysis of Primary Endpoint 
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All data displays and analyses will adhere to the International 
Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Harmonized 
Tripartite Guideline: Structure and Content of Clinical Study Reports 
(ICH Topic E3, July 1996).   
 
5.5 Safety Analyses 
All patients who have received at least one dose of study medication (CPX-351, 
cytarabine or daunorubicin) will be considered evaluable for safety. 
 
Safety endpoints (as defined in section 3.4.7) will be summarized.  Laboratory 
values will be summarized both by actual result and by toxicity grade.  The 
maximum grade for each type of toxicity will be recorded and reported for each 
patient, and frequency tables will be reviewed to determine toxicity patterns 
(Table 9 in Appendix 3.) 
 
The laboratory data, vital signs, ECG, and echocardiography will be 
summarized using descriptive statistics (n, mean, standard deviation, median, 
range) at each scheduled time point (Table 10 in Appendix 3.)  The number and 
proportion of patients with reported AEs will be tabulated by treatment group 
(Table 11 in Appendix 3.) 
 
Early death rates (by Day 30 and 60) will be evaluated separately for each arm 
by the number of deaths occurring in those time intervals divided by the total 
number of patients in the respective arm. 
 
All patients will have serum copper levels assessed at baseline prior to the first 
dose, after the last induction and at Day 150.  Patients with elevated serum 
copper levels (>20% above upper limit of normal) at Day 150 will have monthly 
serum copper determinations until 1 year from randomization or documentation 
of return of serum copper to normal levels. The proportion of patients with 
elevated serum copper levels after the end of treatment with CPX-351 or 7+3 
will be determined for each treatment arm. Comparisons between arms will be 
made using the Mantel-Haenszel test (Mantel and Haenszel, 1959.)  These 
comparisons will be stratified by the stratification factors specified in section 
3.1.  
 
5.6 Additional Endpoint Analyses 
5.6.1 Pharmacokinetics 
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5.6.2 Pharmacoeconomics 
Pharmacoeconomics analysis plan will be outlined in a separate document. 
5.7 Other Issues and Further Details 
5.7.1 Statistical Software used in data analysis 
All analyses will be performed using SAS® Version 9.2 or higher.  CRAB will 
follow the company’s SOPs in the creation and quality control of all tables, 
figures, listings and analyses. 
5.7.2 Timing of Analyses 
An analysis of induction response (CR+CRi) and 60-day death rate will be 
performed approximately 90-120 days after the start of treatment of the last 
randomized patient, which is after all patients have been accrued, treated and 
recovered from induction treatment.  This response analysis will be reviewed 
by the DSMB along with the final study data for 60-day mortality.  The purpose 
of this analysis is to allow decisions to be made for initializing other clinical 
trials of CPX-351.  The sponsor believes that use of response information will 
not bias the conduct of the study because all patients will have been 
randomized, treated and followed long enough to recover from hematopoietic 
effect of treatment and because the remaining data to be collected on each 
patients consists only of relapse and survival which are simple and objective.  
These analyses will not affect the conduct of the trial or the alpha of the 
primary endpoint.  All other analyses including those for overall survival, EFS, 
best response (CR+CRi) and remission duration will be performed after the 
endpoint for the primary analysis has occurred. 
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Appendix 1: WHO Classification of Secondary Acute Myeloid Leukemia 
Therapy related AML: 
Requires more than 20% blood or marrow blasts AND Prior cytotoxic therapy for an unrelated disease: 
• alkylating agents 
• ionizing radiation therapy: large fields including active bone marrow 
• topoisomerase II inhibitors 
• others: antimetabolites, antitubulin agents 
 
Acute myeloid leukemia with myelodysplasia-related changes: 
Requires more than 20% blood or marrow blasts AND any of the following: 
1. Previous history of myelodysplastic syndrome (MDS)requires: 
Bone marrow evidence of dysplasia present 
in ≥10% of cells in one or more myeloid 
lineages or ≥10% dysplastic 
megakaryotypes 
AND/OR 
Unequivocal dysplasia in <10% of cell in one or 
more myeloid cell lines with clonal 
abnormalities characteristic of MDS1
1Clonal abnormalities:  Unbalanced changes:+8*, -7 or del(7q), -5 or del(5q); del(20q)*, -Y*, i(17q) or t(17p), -13 
or del(13q), del(11q), del(12p) or t(12p), del(9q), idic(X)(q13) Balanced changes: t(11;16)(q23;p13.3); 
t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); t(2;11)(p21;q23); inv(3)(q21q26.2), t(6:9)(p23;q34) 
*If the sole cytogenetic abnormality, also needs morphologic criteria with dysplasia present in ≥10% of cells in one 
or more myeloid lineages or ≥10% dysplastic megakaryotypes; all other clonal abnormalities are sufficient for a 
presumptive diagnosis 
OR 
2. With myelodysplastic syndrome-related cytogenetic abnormalities: 
• Complex karyotype (defined as 3 or more chromosomal abnormalities). 
• Unbalanced:  -7 or del(7q); -5 or del(5q); i(17q) or t(17p); -13 or del(13q); del(11q); del(12p) or 
t(12p); del(9q); idic(X)(q13). 
• Balanced:  t(11;16)(q23;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); t(2;11)(p21;q23), 
t(5;12)(q33;p12); t(5;7)(q33;q11.2); t(5;17)(q33;p13); t(5; 10)(q33;q21); t(3;5)(q25;q34) 
OR 
3. With multilineage dysplasia 
• Dysplasia present  in ≥50% of cells in at least two bone marrow cell lines 
• Absence of prior cytotoxic therapy for unrelated disease AND absence of recurring cytogenetic 
abnormalities that meet WHO criteria for AML with recurrent genetic abnormalities. 
 
AML with a history of CMMoL: 
Requires more than 20% blood or marrow blasts AND a history of CMMoL which requires: 
• Peripheral blood monocytosis >1000/μL 
• Absence of Philadelphia chromosome or BCR-ABL1 fusion gene 
• In the presence of eosinophilia, absence of rearrangements of PDGFRA or PDGFRB 
• Presence of dysplasia in one or more myeloid lineages 
• If myelodysplasia is absent/minimal the diagnosis of CMMoL may still be made if the above requirements are 
met and in addition there is the: 
? presence of acquired clonal cytogenetic or molecular genetic abnormality in hematopoietic cells 
OR 
? persistence of monocytosis for ≥3 months and 
? all other causes of monocytosis have been excluded 
• At diagnosis of CMMoL there are fewer that 20% blasts (myeloblast, monoblast, promonocytes) in peripheral 
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Appendix 2: Performance Status – ECOG 
 
Grade Description 
0 Fully active, able to carry on all pre-disease performance without restriction (Karnofsky 90-100) 
1 
Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature (e.g., light housework, office work) 
(Karnofsky 70-80). 
2 
Ambulatory and capable of all self-care but unable to carry out any work 
activities.  Up and about more than 50% of waking hours (Karnofsky 50-
60). 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours (Karnofsky 30-40). 
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Appendix 3: Tables and Figures 
 
Table 1:  Sample summary of demographics and baseline characteristics (categorical variables) 
 
 CPX-351 7+3 All Patients 
Factor 1 n/N (%) n/N (%) n/N (%) 
Factor 2 n/N (%) n/N (%) n/N (%) 
Factor 3 n/N (%) n/N (%) n/N (%) 
Factor 4 n/N (%) n/N (%) n/N (%) 
n/N (%):  n- Number with Factor, N- Number with Valid Data for Factor 
 
 
Table 2:  Sample summary of demographics and baseline characteristics (continuous variables) 
 CPX-351 7+3 All Patients 
Variable N Mean (SD) Median (Range) N Mean (SD) Median (Range) N Mean (SD) Median (Range) 
Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
Variable 3 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
Variable 4 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
 
 








Patients Randomized N N N 
Patients (%) Safety Analysis Set n/N (%) n/N (%) n/N (%) 
Patients (%) Efficacy Analysis Set n/N (%) n/N (%) n/N (%) 
Patients (%) Efficacy Analysis Set for MLS n/N (%) n/N (%) n/N (%) 
Patients (%) Efficacy Analysis Set for Response n/N (%) n/N (%) n/N (%) 
Patients (%) with MLS During Study n/N (%) n/N (%) n/N (%) 
    MLS after First Induction n/N (%) n/N (%) n/N (%) 
    MLS after Second Induction n/N (%) n/N (%) n/N (%) 
    
Reason for Terminating Treatment Phase    
    Adverse Event n/N (%) n/N (%) n/N (%) 
    Consent Withdrawn n/N (%) n/N (%) n/N (%) 
    Protocol Violation n/N (%) n/N (%) n/N (%) 
    Lost to Follow-up n/N (%) n/N (%) n/N (%) 
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    Progressive Disease/Lack of Response n/N (%) n/N (%) n/N (%) 
    Death n/N (%) n/N (%) n/N (%) 
    Other - Transplant n/N (%) n/N (%) n/N (%) 
    Other n/N (%) n/N (%) n/N (%) 
    
Reason for Terminating Study    
    Consent Withdrawn n/N (%) n/N (%) n/N (%) 
    Lost to Follow-up n/N (%) n/N (%) n/N (%) 
    Death n/N (%) n/N (%) n/N (%) 
n/N (%):  n- Number with Factor, N- Number with Valid Data for Factor 
 
 





















(Study Day) Reason for Termination If Other, Specify 












      Death  
      Adverse Event  
      Withdrew Consent  
      Protocol Violation  











Persistent Disease /Lack of 
Response  
      Other XXXXXXXXX 
      Other Transplant 
 
Table 5:  Sample summary of primary and secondary efficacy endpoints 
  
Analysis HR (95% CI) P-value 
Overall Survival (Primary Endpoint Analysis) #.## (#.##, #.##) #.### 
Event-Free Survival (Secondary Endpoint Analysis) #.## (#.##, #.##) #.### 
Remission Duration (Secondary Endpoint Analysis) #.## (#.##, #.##) #.### 
Overall Survival (Sensitivity Analysis) #.## (#.##, #.##) #.### 
Event-Free Survival (Sensitivity Analysis) #.## (#.##, #.##) #.### 
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Table 6: Sample Cox regression analysis 
 
 OS/EFS/Remission Duration 
 Variable n/N (%) HR (95% CI) P-value 
Univariate Univariate Factor 1 n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 2 n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 3 n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 4 n/N (%) #.## (#.##, #.##) #.### 
Multivariate Multivariate Factor 1 n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 2 n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 3 n/N (%) #.## (#.##, #.##) #.### 
 Treatment Arm n/N (%) #.## (#.##, #.##) #.### 
N-Number of patients with available data for specified factor, n-number of patients with specified factor 
HR- Hazard Ratio, 95% CI- 95% Confidence Interval, P-value from Wald Chi-Square Test in Cox Regression 
 
 
Table 7:  Sample summary of secondary efficacy binary endpoints 
 
 CPX-351 7+3 All Patients P-value 
Post induction response (CR+CRi) rate n/N (%) n/N (%) n/N (%) #.### 
Best response (CR+CRi) rate (after 
completion of treatment phase)  n/N (%) n/N (%) n/N (%) #.### 
Morphologic leukemia-free state rate n/N (%) n/N (%) n/N (%) #.### 
Stem cell transplant rate n/N (%) n/N (%) n/N (%) #.### 
n/N (%):  n- Number with Factor, N- Number with Valid Data for Factor 
P-value is for comparison of rates between treatment arms and comes from the Mantel-Haenszel test. 
 
 
Table 8a:  Sample logistic regression analysis for post induction response (CR+CRi) rate 
 
 Post Induction Response (CR+CRi) 
 Variable 






Achieve CR or 
CRi OR (95% CI) P-value 
Univariate Univariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 4  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
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 Post Induction Response (CR+CRi) 
 Variable 






Achieve CR or 
CRi OR (95% CI) P-value 
 Multivariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Treatment Arm  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
N-Number of patients with available data for specified factor, n-number of patients with specified factor  
OR- Odds Ratio, 95% CI- 95% Confidence Interval, P-value from Wald Chi-Square Test in Logistic Regression 
 
 
Table 8b:  Sample logistic regression analysis for best response (CR+CRi) rate (after completion of 
treatment phase) 
 
 Best Response (CR+CRi) after completion of treatment phase 
 Variable 






Achieve CR or 
CRi OR (95% CI) P-value 
Univariate Univariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 4  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
Multivariate Multivariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Treatment Arm  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
N-Number of patients with available data for specified factor, n-number of patients with specified factor  
OR- Odds Ratio, 95% CI- 95% Confidence Interval, P-value from Wald Chi-Square Test in Logistic Regression 
 
 
Table 8c:  Sample logistic regression analysis for morphologic leukemia-free state rate 
 
 Morphologic Leukemia-free State (MLS) 
 Variable 
N (Number of 
patients with 
available data) Achieved MLS
Did Not 
Achieve MLS OR (95% CI) P-value 
Univariate Univariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 4  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
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 Morphologic Leukemia-free State (MLS) 
 Variable 
N (Number of 
patients with 
available data) Achieved MLS
Did Not 
Achieve MLS OR (95% CI) P-value 
 Multivariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Treatment Arm  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
N-Number of patients with available data for specified factor, n-number of patients with specified factor  
OR- Odds Ratio, 95% CI- 95% Confidence Interval, P-value from Wald Chi-Square Test in Logistic Regression 
 
 
Table 8d:  Sample logistic regression analysis for stem cell transplant rate 
 
 Stem Cell Transplant 
 Variable 









Transplant OR (95% CI) P-value 
Univariate Univariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Univariate Factor 4  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
Multivariate Multivariate Factor 1  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 2  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Multivariate Factor 3  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
 Treatment Arm  n/N (%) n/N (%) #.## (#.##, #.##) #.### 
N-Number of patients with available data for specified factor, n-number of patients with specified factor  
OR- Odds Ratio, 95% CI- 95% Confidence Interval, P-value from Wald Chi-Square Test in Logistic Regression 
 
 
Table 9:  Sample toxicity summary 
 
 Treatment Arm A Treatment Arm B 
 Grade Grade 
 1 2 3 4 5 1 2 3 4 5 
System Organ Class Preferred Term  
SOC 1 Overall # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
 Tox Type 1 # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
 Tox Type 2 # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
 Tox Type 3 # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
















Cancer Research And Biostatistics 
 
CLTR0310-301 Statistical Analysis Plan 
 
 
Version 1.0 22 May 2012 Page 31 of 33 
 
Copyright 2007 Cancer Research And Biostatistics (CRAB®).  All Rights Reserved.  Confidential. 
 
 Treatment Arm A Treatment Arm B 
 Grade Grade 
 1 2 3 4 5 1 2 3 4 5 
System Organ Class Preferred Term  
 Tox Type 1 # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
 Tox Type 2 # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) # (##%) 
 
 
Table 10:  Sample summary of safety data 
 CPX-351 7+3 All Patients 
Variable N Mean (SD) Median (Range) N Mean (SD) Median (Range) N Mean (SD) Median (Range) 
PRE-STUDY          
       Lab Data          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Vital Signs          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       ECG          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Echocardiography          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
          
DAY 14          
       Lab Data          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Vital Signs          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
          
DAY 42          
       Lab Data          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Vital Signs          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
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 CPX-351 7+3 All Patients 
Variable N Mean (SD) Median (Range) N Mean (SD) Median (Range) N Mean (SD) Median (Range) 
       Echocardiography          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
          
END OF TREATMENT PHASE          
       Lab Data          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Vital Signs          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       ECG          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
       Echocardiography          
              Variable 1 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
              Variable 2 # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) # #.## (#.##) #.## (#.##, #.##) 
 
 
Table 11:  Sample summary of adverse events 
 CPX-351 7+3 All Patients 
Event 1 n/N (%) n/N (%) n/N (%) 
Event 2 n/N (%) n/N (%) n/N (%) 
Event 3 n/N (%) n/N (%) n/N (%) 
Event 4 n/N (%) n/N (%) n/N (%) 
n/N (%):  n- Number with Factor, N- Number with Valid Data for Factor 
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